Abstractbook Reims2015

ABSTRACTBOOK
Reims, France 13 - 14 April 2015
love
150
150 years
years
Excipients for orally disintegrating tablets.
Contact us via e-mail at pharma-ingredients@basf.com
or visit www.pharma-ingredients.basf.com/odt
| Excipients |
Chairs and Committees

Chair of the Conference
Prof. Jrgen Siepmann, Lille, France
Co-Chairs of the Conference

Prof. Franco Alhaique, Rome, Italy
Prof. Jrg Breitkreutz, Dsseldorf, Germany
Programme Committee Chair

Programme Committee
Prof. Franco Alhaique, Rome, Italy
Prof. Johannes Bartholomaeus, Aachen, Germany
Prof. Anna Maria Fadda, Cagliari, Italy
Dr. Alexandre Gil, Montpellier, France
International Support Pannel

Dr. Eva Roblegg, Graz, Austria
Prof. Chris Vervaet, Ghent, Belgium
Prof. Thomas Rades, Copenhagen, Denmark
Prof. Leena Peltonen, Helsinki, Finland
Prof. Marie-Christine Andry, Reims, France
Prof. Sandra Klein, Greifswald, Germany
Dr. Gza Regdon Jr, Szeged, Hungary
Prof. Elka Touitou, Jerusalem, Israel
Prof. Gaetano Giammona, Palermo, Italy
Prof. Vitalis Briedis, Kaunas, Lithuania
Prof. Malgorzata Sznitowska, Gdansk, Poland
Prof. Joao Pinto, Lisbon, Portugal
Prof. Julijana Kristl, Ljubljana, Slovenia
Prof. Maria Jos Alonso, Santiago de Compostela, Spain
Prof. Anette Larsson, Gothenburg, Sweden
Dr. Rainer Alex, Basel, Switzerland
Prof. Wim Hennik, Utrecht, The Netherlands
Prof. Sema alis, Ankara, Turkey
Prof. Yvonne Perrie, Birmingham, United Kingdom
1st European Conference on Pharmaceutics Drug Delivery

Social programme
Monday, 13 April 2015
17:00
Welcome reception at the Centre des Congrs Reims

The Welcome Reception will be held in the exhibition halls of Centre des Congrs Reims (La Nef).
Enjoy a glass of champagne while networking with old and new friends.
Opening hours: business office and registration desk

Monday
13 April 2015
07:00 to 20:00
Tuesday
14 April 2015
08:00 to 17:00
Level 0 : R E C E P T I O N
BOULEVARD MAURICE NOIROT
Access by lift
for handicapped persons
Access to underground
car park
car park by stairs
LUGGAGE ROOM
STORAGE
car park by lift
RECEPTION DESK
Handicapped
persons
access
RECEPTION SPACE
RIA
Badge checkpoint
& access
to building
Lobby
MAIN ENTRANCE
Coffee
machine
PARC DE LA
PATTE D'OIE
0 1m
5m
10m
15m
20m
12.10 - Centre des congrs de Reims


Amphithtre Royal
09:00 Opening Ceremony and APGI Student Award
Jrg Breitkreutz, President of APV
Franco Alhaique, President of A.D.R.I.T.E.L.F.
Jrgen Siepmann, President of APGI
Arnaud Robinet, Mayor of Reims
09:15 Plenary lecture
Chair: F. Alhaique
Drug Targeting - Where are we?
Patrick Couvreur, Chtenay-Malabry (Paris), France
10:15 Coffee break (La Nef)
Poster session and industrial exhibition
10:45 Invited talks: Transdermal Drug Delivery
Chairs: A. M. Fadda/H. Franke
10:45 Transdermal drug delivery: A Mature and Evolving Technology
Richard Guy, University of Bath, Bath, United Kingdom
11:25 Transdermal Drug Delivery: An Industrial Viewpoint
Michel Sournac, Pierre Fabre, Toulouse, France
12:05 The new Guideline on Quality of Transdermal Patches:
New Requirements in Development
Sean Jones, Medicine and Healthcare Products Regulatory Agency, London, United Kingdom
12:45 Lunch break (La Nef)
15:00 Invited talks: Oral Drug Delivery
Chairs: D. Craig/S. Page
15:00 Recent Challenges in Oral Controlled-Release Drug Delivery
Martin Lueck, Gruenenthal, Aachen, Germany
15:40 Therapeutic Index Issues around Oral Peptide Permeation Enhancers
David Brayden, University of Dublin, Dublin, Ireland
16:20 Orodispersible Dosage Forms
Dejan Djuric, Bayer, Berlin, Germany
17:00 End of session
17:00 Welcome Reception with Champagne Tasting in the exhibition area (La Nef)
Amphithtre Clovis
10:45 Short talks: Oral Controlled Drug Delivery
Chairs: C. Caramella/P. Lefevre
10:45 How does the drinking volume affect gastric dissolution in infants?
New in vitro approaches for preclinical screening
E. Kersten and S. Klein
11:05 In-vitro dissolution testing of oral thin films (OTFs): theory and experiments
A. Adrover, M. Casadei, S. Pacelli, P. Paolicelli, S. Petralito and R. Spera
11:25 Proposal for a new dissolution method for soft chewable delivery systems
C. Stomberg, E. Melzer, J. Radtke and P. Kleinebudde
11:45 Assessing Softgel Disintegration in the Gastric Compartment:
Correlating the Dynamic Gastric Model with In Vivo Visualization by Camera-Capsules
H. Teles, K. van den Dries, S. Chessa, D. Bar-Shalom, H. Huatan, P. Sassene and A. Mllertz
12:05 Mucoadhesive polymeric nanocomposites for oral delivery of S-nitrosoglutathione
W. Wu, C. Gaucher, I. Fries, X. Hu, Y. Xiao, p. Maincent and A. Sapin-Minet
12:25 Amphiphilic Nucleic Acid Conjugates for Local Treatment of Intestinal Diseases
E. Moroz, S. Lee, H. Jahns, J. Hall, K. Yamada, M. Damha, B. Castagner and J. Leroux
15:00 Short talks: Nanoparticles & Vesicles
Chairs: N. Dragicevic-Curic/C. Lemarchand
15:00 The effect of using different nebulisers on the delivery of Amphotericin B
and Cisplatin Non-Ionic Surfactant Vesicles
M. Puig, C. Carter and A. Mullen
15:20 Ex vivo and in vivo siRNA delivery to activated T cells as novel
anti-inflammatory asthma therapy
Y. Xie, N. Kim, A. Thakur, L. Lum, D. Bassett and O. Merkel
15:40 Chitosan-iron-based nanogels for the cellular delivery of polyphosphate drugs
G. Giacalone, H. Hillaireau, A. Bochot and E. Fattal
16:00 Anti-E6/E7/MCL1 pegylated lipoplexes for a vaginal treatment of cervical cancer
A. Lechanteur, T. Furst, B. Evrard, P. Delvenne, G. Piel and P. Hubert
16:20 Delivery of Andrographolide to the brain by human serum albumin nanoparticles
M. Bergonzi, C. Guccione, V. Piazzini, A. Torracchi, C. Grossi, F. Casamenti and A. Bilia
16:40 Percutaneous absorption of benzophenone-3 loaded lipid nanoparticles and
polymeric nanocapsules: a comparative study
E. Gilbert, L. Roussel and F. Pirot
17:00 Welcome Reception with Champagne Tasting in the exhibition area (La Nef)
6

Tuesday, 14 April 2015

Amphithtre Royal
09:00 Invited talks: Smart Drug Delivery Systems
Chairs: T. Rades/J. Voorspoels
09:00 Progresses in Anticancer Drug Delivery by Polymer Conjugation
Gianfranco Pasut, University of Padova, Padova, Italy
09:40 3D Printing
Clive Roberts, University of Nottingham, Nottingham, United Kingdom
10:20 Smart Drug Delivery from an industrial perspective
Paul Gellert, AstraZeneca, Macclesfield, United Kingdom
11:30 Plenary lecture
Chair: J. Breitkreutz
Advances in Pulmonary Drug Delivery
Hartmut Derendorf, Gainesville, Florida, United States
15:00 Invited talks: Peptide and Protein Delivery
Chairs: P. Matricardi/M. Lueck
15:00 Protein and Peptide Delivery: Current State of the Art
Wim Hennink, University of Utrecht, Utrecht, The Netherlands
15:40 Challenges and advances in vaccine delivery
Derek O Hagan, Novartis Vaccines and Diagnostics Inc., Cambridge, United States
16:20 Novel Application Systems for Transdermal Vaccine Delivery
Heiko Spilgies, LTS Lohmann Therapie-System AG, Andernach, Germany
Amphithtre Clovis
09:00 Short talks: Advanced Drug Delivery
Chairs: K. Andrieux/G. Verreck
09:00 Modifications of the stratum corneum barrier structure and function introduced
by freezing: consequences for drug permeation studies
L. Roussel, R. Abdayem, N. Zaman, E. Gilbert, F. Pirot and M. Haftek
09:20 IN VITRO PHAGE DISPLAY AS A STRATEGY TO ENHANCE

THE SKIN PENETRATION OF HEPARINS
S. Franz, C. Gennari, S. Pellegrino, F. Cilurzo and P. Minghetti
09:40 Hyaluronic acid gels containing liposomes for the sustained delivery
of a corticoid to the inner ear
N. El Kechai, F. Agnely, E. Mamelle, V. NIcolas, N. Huang, Y. Nguyen, E. Ferrary and A. Bochot
10:00 MESOPOROUS PHOSPHOLIPID PARTICLE AS A NOVEL DRUG DELIVERY PLATFORM
K. Kawakami, S. Zhang, G. Jayakumar, M. Fukushima, J. Hill and K. Ariga
10:20 THALIDOMIDE NASAL POWDERS FOR LOCAL TREATMENT OF NOSE BLEEDING IN
HEREDITARY HEMORRHAGIC TELANGECTASIA
V. Chiapponi, A. Rossi, G. Colombo and P. Colombo
10:40 In vitro estimation of drug delivery to stenosed coronary blood vessels via
drug-coated balloon catheters
A. Seidlitz, W. Kempin, T. Reske, S. Kaule, N. Grabow, S. Petersen, S. Nagel
and W. Weitschies
11:30 Plenary lecture (Amphithtre Royal)
Chair: J. Breitkreutz
Advances in Pulmonary Drug Delivery
Hartmut Derendorf, Gainesville, Florida, United States
15:00 Short talks: Development & Manufacturing of Solid Dosage Forms
Chairs: M. Repka/P. Gellert
15:00 Thermodynamics of API/Polymer Amorphous Formulations
G. Sadowski
15:20 Hot-melt extrusion of polyvinyl alcohol and plasticizer for oral immediate
release applications
W. De Jaeghere, T. Monteyne, T. De Beer, J. Remon and C. Vervaet
15:40 Melt blowing and electrospinning for dissolution enhancement
A. Balogh, B. Farkas, Z. Nagy, G. Marosi, I. Assche and G. Verreck
16:00 Exploring the Use of Pressurised Gyration for Large Scale Manufacture of
Pharmaceutical Nanofibres
B. Raimi-Abraham, S. Mahalingam, M. Edirisinghe and D. Craig
16:20 PAT tools for the control of the manufacturing processes of co-extruded implants,
tablets and capsules
F. Krier, A. Pestieau, G. Thoorens, T. Justine, D. Anas, T. Marion, M. Jrme, E. Ziemons,
P. Hubert and B. Evrard
16:40 The Application of Novel nano-Thermal and Imaging Techniques for Monitoring
the Drug Distribution within PLGA Microspheres
M. Zhao, F. Yang, D. Chen, Z. Guo, Y. Zhang and D. Craig
8

Posters
Posters
Exhibited continuously from 9:00 to 20:00, with special sessions from 12:45 to 15:00.
The number indicates the number displayed on the poster panel.
Advanced Drug Delivery Systems

1
Lipid-based formulations as a way to improve the solubilization of cinnarizine

S. Siqueira, G. Kasten, T. Rades, H. Mu and A. Mllertz
A new RNA delivery platform for tumor immunotherapy

H. Haas, K. Buch, I. Esparza, D. Fritz, M. Meng, L. Kranz, K. Reuter, M. Diken,
S. Kreiter and U. Sahin
Anti-inflammatory properties of synbiotic loaded chitosan-Ca-alginate

microparticles in animal model of colitis
T. Petreska Ivanovska, Z. Zhivikj, M. Jurhar Pavlova, M. Glavas Dodov, T. Ristoski, I. Gjurovski,
L. Petrushevska-Tozi and K. Mladenovska
Cationic lipid-free cationic nanoemulsions - a novel approach for the treatment of

ophthalmic infections
X. Li, N. A. Bou-Chacra, R. H. Mller and C. M. Keck
Charge reversal inulin-doxorubicin conjugate as tailor-made tool for cancer

targeted therapy
N. Mauro, C. Scialabba, M. Licciardi, G. Giammona, G. Adamo, S. Campora and G. Ghersi
Development and characterization of SEDDS containing babassu oil associated with

copaiba oil for treatment of benign prostatic hyperplasia
L. Abreu, F. Carmo and L. Cabral
DEVELOPMENT AND CHARACTERIZATION OF SELF NANOEMULSIFYING SYSTEM (SNEDDs)

FOR ROSUVASTATIN
H. Y. KARASULU, E. GUNDOGDU, T. TURGAY, S. APAYDIN, U. O. TURK, I. YILDIRIM SIMSIR,
C. YILMAZ and E. KARASULU
Development of internally self-assembled lipid-based systems for vaccine delivery

L. Pires Rodrigues, K. Kyriakos, C. Papadakis, G. Winter and M. Hubert
Development of microsponges as drug delivery carriers using multivariate analyses

M. Simonoska-Crcarevska, E. Mitanovksa-Janeva, N. Sibinovska, V. Komoni, N. Geskovski,
S. Dimcevska, K. Mladenovska, R. Slaveska-Raicki, S. Trajkovic-Jolevska and M. Glavas-Dodov

10
Development of mucoadhesive drug delivery systems by precipitation of chitosan

on drug-loaded microparticles
D. Preisig, M. Weingartner, F. J. Varum, R. Bravo, R. Alles, M. Puchkov and J. Huwyler
11
Does cinnarizine form amorphous complexes with lipids during digestion of

lipid-based drug delivery systems?
P. Sassene, M. Mosgaard, K. Lbmann, H. Mu, F. Larsen, T. Rades and A. Mllertz
12
Drug delivery in UTI treatment new perspectives by mimicking uropathogenic

Escherichia coli cytoinvasion
C. M. Pichl, C. Apfelthaler, B. Dunkl, B. Brauner, F. Gabor, M. Wirth and L. Neutsch
13
Drug-Loaded Silica for Oral Formulations

D. Lubda, R. Ognibene, G. Birk, M. Wagner, S. Kucera, F. Bauer and M. Zheng
14
Dry Coating for Taste-Masking of Bitter Drugs with Hydroxypropyl Cellulose Powders
H. Ichikawa, T. Andoh, Y. Fukumori, B. Ehlig, S. Kodama, S. Tsue and K. Sugisawa
15
Embedding of a poorly water-soluble drug in silica particle systems for the application
in orodispersible films
J. H. Finke, S. Melzig and A. Kwade
16
FUSED DEPOSITION MODELING (FDM) FOR 3D PRINTING OF DRUG DELIVERY CAPSULES

A. Melocchi, F. Parietti, G. Loreti, A. Maroni, L. Zema and A. Gazzaniga
17
Generation and characterization of small single domain antibodies inhibiting human

TNF receptor 1.
S. Steeland, L. Puimge, R. Vandenbroucke, F. Van Hauwermeiren, J. Haustraete, N. Devoogdt,
D. Laukens, P. Meuleman, M. Devos and C. Libert
18
How to Easily Provide Zero Order Release of Freely Soluble Drugs from Coated Pellets
B. Dekyndt, J. Verin, C. Neut, F. Siepmann and J. Siepmann
19
Improving the delivery of vaginal dosage forms

H. STRAUB and D. CADE
20
In situ Gel Formulation for Intravesical Gemcitabine Hydrochloride Installation

S. Y. Karavana, Z. Ay S enyigit, . aliskan and E. Baloglu
21
In situ liposomes from novel pre-liposome tablets for vaginal drug delivery
Z. Vanic, N. Skalko-Basnet and I. Tho
22
Influence of size and protein concentration on the cross-linking degree of serum

albumin microcapsules
F. Deshayes, E. Charpentier, E. Bourguet and F. Edwards-Lvy
23
Influence of the Ester Group Structure of Modified Alginates on the Preparation of

Microparticles by Transacylation with Serum Albumin
I. HADEF, M. OMRI, C. BLIARD, B. ROGE and F. EDWARDS-LEVY
24
Interaction studies of Memantine loaded biodegradable polymeric nanoparticles

M. A. Egea, E. Snchez, M. Espina, N. Carmona, G. Ramos, A. C. Calpena and M. L. Garca
25
Lipid self-assembled structures as carriers for antimicrobial peptides

L. Boge, H. Bysell, L. Ringstad and M. Andersson
10

26
Lyophilized microemulsions: the influence of heating on the droplet size and

phase transition
A. Rochelle do Vale Morais
27
Microcontainers improve oral bioavailability of furosemide

L. Hagner Nielsen, A. Melero, S. Sylvest Keller, A. Mllertz and A. Boisen
28
Mucoadhesion of thiolated poly(aspartic acid) polymers for ophthalmic use

G. Horvt, B. Gyarmati, B. Szilgyi, T. Csihi, G. Sandri, M. C. Bonferoni, C. Caramella, A. Szilgyi,
E. Csnyi and M. Budai-Szucs
29
Nanotubes-in-Microgel Oral System (NiMOS) by prilling for Protein Delivery

J. K. de Kruif, G. Ledergerber, C. Garofalo and M. Kuentz
30
New Two Piece Enteric Drug Delivery Capsules: Human gamma-scintigraphy and
pharmacokinetic evaluation
A. Sivert, P. Dfossez, M. Clauzel, D. Nombret, D. Cad and H. Benameur
31
Phosphorous dendrimers siRNA complexes for treatment of chronic inflammation

A. Bohr, N. Tsapis, A. Chamarat, J.-P. Majoral, C. Foged and E. Fattal
32
PLATELET LYSATE EMBEDDED SCAFFOLD FOR WOUND HEALING: IN VITRO AND

PRELIMINARY IN VIVO CHARACTERIZATION
G. Sandri, F. Saporito, M. C. Bonferoni, S. Rossi, F. Ferrari, M. Mori, I. Liakos, C. Boselli,
A. Invernizzi and C. Caramella
33
PREPARATION OF MODIFIED RELEASE DRUG LOADED HPMC-AS MATRIX

MICROPARTICLES SUITABLE FOR PRECLINICAL DELIVERY
S. Sood, C. Freire and M. Saunders
34
Redox-responsive mesoporous silica as carriers for controlled drug delivery

Y. Wang, Q. Zhao, Y. Gao, B. Hou, J. Zhang and S. Wang
35
Serum Albumin-Alginate Microparticles Prepared by Transacylation:

Effect of Polymer Interfacial Interactions
I. HADEF, B. ROGE and F. EDWARDS-LEVY
36
Serum Albumin-Alginate Microparticles Prepared by Transacylation: Physicochemical

and Structural Properties
I. HADEF, B. ROGE and F. EDWARDS-LEVY
37
Smart ruthenium nanodrugs for tumor targeted delivery: a new approach to fight cancer
A. Valente, M. H. Garcia, F. Marques, A. Matos and P. Zinck
38
SmartCrystals - stability in dermal hydrogels and creams

X. Li, X. Zhai, R. H. Mller and C. M. Keck
39
SOLVENT FREE APPROACH FOR ENHANCEMENT OF DRUG SOLUBILITY USING

MESOPOROUS SILICA
F. Monsuur, Y. Choudhari and W. McCarthy
40
Synthesis and Characterization of Poly(-Caprolactone)- vitamin E TPGS Copolymers

for Potential Applications in Drug Delivery
Z. Binkhathlan

11
41
Targeted Poly-(L)-glutamic acid drug delivery systems for intravesical therapy of

non-muscle invasive bladder cancer
C. Apfelthaler, C. M. Pichl, P. Gassenbauer, F. Gabor and M. Wirth
42
The drug-initiated method: a convenient approach for the synthesis of efficient

polymer prodrug nanoparticles
D. T. Bui, S. Harrisson, A. Maksimenko, P. Couvreur and J. Nicolas
Controlled Drug Delivery

43
A Mechanistic Model for Drug Release Using Spherical Particles Made of PLGA
K. SEVIM and J. PAN
44
CHARACTERIZATION OF SUPRAMOLECULAR SYSTEMS CONTAINING FENBUFEN,

PLURONIC AND CYCLODEXTRINS
A. Figueiras, S. Nunes, S. Simes, A. Pais and F. Veiga
45
Controlled release from drug/Eudragits delivery systems

Y. Ji, M. Lemberg, A. Prudic and R. Paus
46
Controlled Release Implants prepared by compression of spray-dried PLGA/water-soluble

polymer microparticles
M. Hamoudi, R. Pattacholi, C. Debraize and J. Siepmann
47
Controlled release of quercetin encapsulated in biopolymer films modulated by

electron beam irradiation
N. Benbettaieb, T. Karbowiak, A. Assifaoui, F. Debeaufort and O. Chambin
48
Core shell coated chitosan microspheres at low pH durability for controlled drug release
M. nal
49
Development of novel formulations for organoboron drugs by association

to anionic clays
S. Sn, S. Bgu, C. Gervais and D. Laurencin
50
Drug release from PEO-hot melt extrudates: impact of the drug loading
O. Cantin, F. Siepmann, F. Dande, Y. Karrout and J. Siepmann
51
Factors Shaping the Release Profile from Film Coated Pellets Controlling Drug Release
Through Cracks
S. Muschert, F. Siepmann, Y. Rosiaux, A. Axelsson and J. Siepmann
52
Hot Melt Extrusion can Provide More Robust Drug Release from PEO Matrices than
Direct Compression
O. Cantin, F. Siepmann, Y. Karrout and J. Siepmann
53
Importance of Diffusion and Limited Drug Solubility in Silicone Matrices for

Cochlear Implants
M. Gehrke, J. Sircoglou, C. Vincent, J. Siepmann and F. Siepmann
54
In vitro accelerated drug release from parenteral levonorgestrel butanoate suspensions

K. Tietz, D. Friend and S. Klein
12

55
Influence of controlling agent and fillers on acetylsalicylic acid release kinetics

from matrix tablets
J. Conceio, S. Fernandes, P. Costa and J. M. Sousa Lobo
56
INFLUENCE OF POLYMERIC COMPOSITION IN BENZNIDAZOLE RELEASE FROM MODULAR

ASSEMBLED FLOATING DELIVERY SYSTEM
A. C. Melo-Miranda, M. A. Segatto-Silva, P. Colombo and A. Rossi
57
Novel polymeric carriers for the sustained release of an antipsychotic drug

D. Bikiaris, P. Siafaka, M. Lazaridou, C. Koulouktsi, G. Papageorgiou, E. Koutris and E. Karavas
58
Release Study and Anti-inflammatory Activity of Pentacyclic Triterpenes

H. L. Alvarado Bonilla, G. Abrego Escobar, A. Parra Coca, L. E. Sosa Diaz, M. L. Garduo Ramirez,
B. Clares Naveros, A. C. Calpena Campmany and M. L. Garcia Lopez
59
Slow-release drug-loaded mini-tablets for ocular use: effect of polymer particle size
on formulation behaviour
A. S. Mohmad Sabere, S. Barker and D. Craig
60
Sustained Release Formulations for a New Broad-Spectrum Antibacterial Agent

against Colitis
M. S. Nieto Bobadilla, F. Siepmann, M. Djouina, L. Dubuquoy, J. Siepmann, L. Dubreuil
and C. Neut
61
Synthesis and characterization of S-nitrosoglutathione-alginate as an NO donor

S. U. SHAH, M. SOCHA and S. GIBAUD
62
Why increasing drug loadings might lead to faster drug release from Kollicoat SR
coated pellets
J. Fahier, C. Velghe, S. Muschert, G. Byrne, F. Siepmann and J. Siepmann
63
Why sugar cores might lead to slower drug release from coated pellets compared
to MCC cores
J. Fahier, C. Velghe, S. Muschert, G. Byrne, F. Siepmann and J. Siepmann
Oral Delivery
64
An investigation of interaction between ibuprofen and modified diatomite:

potential drug carrier
J. Janicijevi
c,
D. Krajinik, B. ?alija, V. Dobrici c and J. Mili c
65
Development of a Bioequivalent Montelukast 5mg Zydis Dosage Form

A. Cusack and L. Grother
66
Development of a coated ODT nutraceutical formulation

J. CAMARGO, G. WEISS, G. LE BIHAN and P. LEFEVRE
67
Effect of curcumin encapsulation in whey protein-pectin beads upon their properties

with intestinal medium
B. Fernandez, T. A. Nguyen, Y. Wach, M. Subirade, I. Fliss and O. Chambin
68
Effect of digestion on absorption of halofantrine from SNEDDS and super-SNEDDS

in a rat model
M. H. Michaelsen, K. Wasan, T. Rades and A. Mllertz

13
69
Encapsulation of anthocyanins from purple corn cob by spray drying and release studies
of encapsulated powder
N. Kapcum, J. Uriyapongson, M. Meenune, G. Roudaut and O. Chambin
70
Evaluating different manufacturing options to formulate loperamide HCl as orally

disintegrating tablet
T. Agnese and T. Cech
71
Evaluating poly(vinyl acetate) as taste masking agent for paracetamol formulated in

chewable tablets
F. Bang, T. Cech and M. Mistry
72
Evaluating various disintegrants regarding their performance in orally disintegrating

tablet formulations
T. Agnese, F. Bang, T. Cech and M. Mistry
73
Evaluating various wet binders to gain lactose based agglomerates applicable for orally
disintegrating tablet formulations
T. Agnese, T. Cech and M. Mistry
74
Examination of the behaviour of hydroxypropyl cellulose free films with lidocaine base
for oral use with thermal analysis method
G. Regdon, jr., M. Gottnek and K. Pintye-Hdi
75
Experimental design of self-nanoemulsifying drug delivery systems containing

monoacyl phosphatidylcholine
T. T. Tran, T. Rades and A. Mllertz
76
HOT MELT EXTRUSION TECHNOLOGY (HME): DISSOLUTION RATE ENHANCEMENT OF

RITONAVIR IN GASTRIC pH WITH EUDRAGIT EPO
D. Jaiswar, P. Amin, M. Seervi, D. Sarvaiya, H. Kundaikar and A. Gangurde
77
Hydroxypropyl methyl cellulose based Efavirenz Solid Dispersions by Hot Melt Extrusion
and Spray drying Technique: Physical Characterization and Insilico study
S. Javeer, H. Kundaikar, A. Gangurde, J. Pawar, M. Degani and P. Amin
78
Ibuprofen self-emulsifying pellets prepared with colloidal silicon dioxide/microcrystalline

cellulose and triglycerides
A. PANAGOPOULOU, K. MAVRIDOU, T. AVGERINOS and I. NIKOLAKAKIS
79
Influence of Artificial Saliva on Taste Masking Studies

M. Khaydukova, L. I. Immohr, D. Kirsanov, A. Legin and M. Pein
80
Influence of pore former and sintering temperature on the mechanical properties of

hydroxyapatite tablets
K. Kachrimanis, N. Kantiranis, C. Grammenos and I. Nikolakakis
81
Low density floating matrix tablets prepared by hot melt extrusion

W. Kriangkrai, S. Puttipipatkhachorn, P. Sriamornsak, F. Siepmann, J. Siepmann and
S. Sungthongjeen
82
MESOPOROUS SILICA GEL AS FORMULATION AID FOR MOISTURE SENSITIVE

DRUG/EXCIPIENT
F. Monsuur, Y. Choudhari and W. McCarthy
14

83
Milk protein-pectin beads a novel means for curcumin encapsulation

T. A. Nguyen, T. U. Huynh, P. Winckler, Y. Wach, M. Subirade and O. Chambin
84
Mucoadhesive films for treatment of oral infections containing vermiculite/chlorhexidine

nanocomposites
J. Gajdziok, H. Landov, P. Doleel and D. Vetch
85
New Enteric Coating Method with AQOAT (HPMCAS)

V. Henner, A. Sauer and S. Kikuchi
86
Novel fenofibrate-gelatin microcapsules with improved solubility and excellent flow

property: preparation, physicochemical characterization and pharmacokinetic evaluation
A. Yousaf, D. W. Kim, T. Ramasamy, O. Mustapha, F. Din, J. O. Kim, C. S. Yong and H.-G. Choi
87
Overcome the Color Stability Issue Exhibited by Indigo Carmine: AquariusTM Preferred
HSP Film Coating System
T. Tuglu, N. Ekmekciyan, E. Stoyanov and S. Porter
88
Overcoming Disintegration Challenges in an Oral Biologic Tablet Formulation

A. Balasundaram, J. Sutch and K. Van den Dries
89
Preparation of Fast Dissolving Drug-Loaded Sucrose Fibers using a Cotton-Candy

Floss Machine
S. Marano, D. Craig, S. Barker, B. T. Raimi-Abraham, S. Missaghi and A. Rajabi-Siahboomi
90
Preparation of lysozyme enzyme containing orally disintegrating tablets

I. Olh, J. Lasher, G. Baki, A. Kenneth, T. Sovny, K. Pintye-Hdi and G. Regdon Jr
91
Process integration for the improved production of nanoparticle-loaded

orodispersible films
D. Steiner, J. H. Finke and A. Kwade
92
Protein distribution in solid lipid microparticles visualized using coherent

anti-Stokes Raman scattering
P. C. Christophersen, D. Birch, J. Saarinen, A. Isomki, H. M. Nielsen, M. Yang, C. J. Strachan
and H. Mu
93
Quality by Design (QbD) approach to optimize the disintegration time of enteric

coated capsules
T. Dassinger, N. Hauschildt and T. Kuntz
94
QUATERNARY POLYMETHACRYLATE - ALGINATE COATED TABLETS: EFFECT OF ALGINATE

BLOCK STRUCTURE ANG CURING ON DRUG RELEASE
T. Pongjanyakul, R. Khlibsuwan and N. Khuathan
95
Simple Process Changes to Overcome Reduced Dissolution of Agglomerating

Micronized API
J. Sutch, A. Balasundaram and K. van den Dries
96
SPRAY-DRIED CHITOSAN-MAGNESIUM ALUMINUM SILICATE COMPOSITE TABLETS:

EFFECT OF CHITOSAN MOLECULAR WEIGHT
R. Khlibsuwan and T. Pongjanyakul

15
97
STUDIES ON DISSOLUTION RATE ENHANCEMENT, PHYSICOCHEMICAL

CHARACTERIZATION, AND IN-SILICO MOLECULAR MODELLING OF ARTEMETHER
USING HYDROPHILIC CARRIERS.
J. PAWAR, R. SHETE, H. KUNDAIKAR, S. JAVEER, A. GANGURDE, M. DEGANI and P. AMIN
98
Study of the relationships among mechanical and texture properties of mucoadhesive

oral films using multivariate data analysis
D. Vetch, J. Gajdziok, P. Doleel and H. Landov
99
The influence of polysaccharide carrier on solid SMEDDS characteristics and on

dissolution profile of naproxen
M. Gaperlin, K. Cerpnjak,
F. Vrecer
and A. Zvonar
100 The role of different salts in drug release from -carrageenan matrices
S. De Robertis, L. Elviri and R. Bettini
101 Type III lipid-based formulations design for oral delivery of acyclovir
J. Jankovic, L. Djekic and M. Primorac
102 Type III lipid-based formulations for oral delivery of high-dosage drugs: design and
in vitro evaluation
L. Djekic, J. Jankovic and M. Primorac
103 Understanding the formation of co-amorphous drug-amino acid formulations
K. Tarp Jensen, K. Lbmann, H. Grohganz and T. Rades
104 D/A Model to Evaluate Absorption Effects from a Transient Supersaturated State
R. Berthelsen, A. L. Slot and A. Mllertz
Pulmonary Delivery
105 A framework for a Biopharmaceutical Classification of Antibiotics for Pulmonary Delivery
S. M. Marchand, J. Brillault, N. Grgoire, I. Lamarche, P. Gobin and W. Couet
106 Aerodynamic and structural evaluation of microcomposites containing
meloxicam potassium
R. Ambrus, A. Chvatal, A. Pomzi and P. Szab-Rvsz
107 Ciprofloxacin-loaded mineral calcium-hyaluronan composite microparticles to treat
chronic bacterial lung infection
F. Tewes, J. Brillault, B. Lamy, P. OConnell, J.-C. Olivier, W. Couet and A. M. Healy
108 Compared toxicity of lung delivered nanoparticles, biodegradable or not: in vitro
and in vivo studies
H. Hillaireau, N. Grabowski, L. A. Santiago and E. Fattal
109 Construction of amikacin dry powders for inhalation by a Central Composite Design
S. Belotti, A. Rossi, P. Colombo, R. Bettini, D. Rekkas, S. Politis, G. Colombo, A. G. Balducci
and F. Buttini
110 CYCLODEXTRINS INHALATION PREVENTS ALLERGEN-INDUCED INFLAMMATION AND
AIRWAY HYPERRESPONSIVENESS ASSOCIATED WITH ASTHMA
G. Dufour, N. Rocks, S. Ormenese, C. Leonard, M.-P. Mingeot-Leclercq, D. Cataldo and B. Evrard
16

111 Development of dry powder carrier systems for pulmonary application

R. Ambrus, B. Szab and P. Szab-Rvsz
112 Development of Theophylline Effervescent Powder for Pulmonary Drug Delivery
J. Napaporn, T. Seetawun, P. Tarnsuwan and W. Junkheiw
113 Effect of polymeric nanoparticles on the stability of biomimetic models of the
lungs surfactant
W. Daear, P. Lai, M. Anikovskiy and E. J. Prenner
114 FORMULATION AND CHARACTERIZATION OF ANTIBIOTIC AND MUCOLYTIC CONTAINING
DRY POWDER INHALER FORMULATIONS
Y. Akdag Cayli, S. Sahin, I. Vural and L. Oner
115 Formulation of levofloxacin-loaded chitosan microspheres for pulmonary delivery
M. Da Costa Gaspar, A. Pais, J. Sousa, F. Tewes and J.-C. Olivier
116 Inhaled SLM for anti-TB therapy by DPI device: process parameters affecting
freeze-drying and breathability
E. Maretti, E. Porcheddu, E. Imbuluzqueta, A. G. Balducci, F. Buttini, F. Sacchetti, M. Romagnoli,
E. Leo and V. Iannuccelli
117 Lecithin/TPGS-based spray-dried SMEDDS for lung cancer: in vitro pulmonary deposition
and cytotoxicity
R. Ishak and R. Osman
118 Microencapsulated rifabutin-loaded lipid nanoparticles for inhaled therapy
D. Gaspar, P. Taboada, A. Almeida and C. Remun-Lpez
119 Nanomicelle-based dry powders for inhalation for targeted delivery to lung cancer cells:
in vitro evaluation and in vivo local pulmonary tolerance on healthy mice
R. Rosire, M. Van Woensel, I. Langer, V. Mathieu, K. Amighi and N. Wauthoz
120 Nebulization characteristics of surface modified liposomes optimized for pulmonary
drug delivery
B. Lehofer, P. P. Jain, F. Bloder, R. Leber, L. M. Marsh, H. Olschewski, A. Olschewski and R. Prassl
121 Polyaspartamide based microparticles for Tobramycin delivery to the lung in FC therapy
C. Sardo, M. Licciardi, E. G. Di Domenico, D. De Rocco, P. Del Porto, F. Ascenzioni, G. Giammona
and G. Cavallaro
122 Polymeric micelles based on a polyaspartamide copolymer for pulmonary delivery of
beclomethasone dipropionate
D. Triolo, C. Sardo, E. F. Craparo, G. Giammona and G. Cavallaro
123 Rifabutin-loaded solid lipid nanoparticles for pulmonary delivery
D. Gaspar, V. Faria, L. Gonalves, C. Remun-Lpez and A. Almeida
Dermal preparations
124 Application of factorial design methodology in transdermal absorption: optimization of
skin absorption from cosmetic/pharmaceutical formulations
F. Laredj and M. Salmon

17
125 Azithromycin smartCrystals for prevention of infections by tick bites

N. Jin, S. Staufenbiel, C. M. Keck and R. H. Mller
126 Characterization and Ex-Vivo Permeation Studies of Melatonin-Incorporated
Elastic Niosomes
G. Arslan Azizoglu,
S. Tuncay Tanriverdi and . zer
127 Confocal Raman Microscopic (CRM) methodology for the analysis of the penetration of
pharmaceutical actives into the skin
D. Lunter
128 Development of sulphur-salicylic gel systems as new bioactive formulations for the
topical treatment of acne vulgaris
R. Langasco, G. Spada, S. T. Tanriverdi, O. Ozer, P. Giunchedi and E. Gavini
129 Development, Characterization and Skin Delivery Studies of Related Ultradeformable
Vesicles: Transfersomes, Ethosomes and Transethosomes
A. Ascenco, S. Raposo, C. Baptista, P. Cardoso, T. Mendes, F. Praa, M. Bentley and S. Simes
130 Employing Pickering emulsions as carrier system for retinol palmitate and
-tocopherol acetate
J. Schfer, T. Agnese, T. Cech and T. Schmeller
131 Enhanced Delivery of Actives to Skin with Silicone Technologies
M. EEMAN, H. ALIYAR, M. LE MEUR and X. THOMAS
132 Glycolic acid in alkyl polyglucosed based vehicle
M. Lukic, T. Isailovic, I. Pantelic, R. Daniels and S. Savic
133 Improved Treatment of Atopic Dermatitis with Corticosteroid Loaded Liposomes
I. Eroglu,
E. Azizoglu, M. zyazici, M. Nenni, H. Grer Orhan, S. zbal, I. Tekmen, I. Ertam,
I. nal and . zer
134 In-vitro study of imiquimod skin retention
S. Nicoli, I. Tel, C. Padula and P. Santi
135 Investigating the impact of phosphate buffer on the gel
F. Bang, T. Cech and F. Soergel
136 Investigation of physico-chemical characteristics of W/O liquid emulsion with high
hydrating effect
B. Vucelic, J. Bjeletic, N. Dragicevic-Curic and M. Bajcic
137 Microencapsulated haiir dyes: safety and efficacy
M. Centini, E. Hanno, F. Francescon and C. Anselmi
138 Nanoemulsion with clotrimazole - design and optimalization the mean droplet size
using high pressure homogenizer
K. Sosnowska, E. Szymanska
and K. Winnicka
139 Nanosuspensions improve diclofenac dermal delivery
R. Pireddu, F. Lai, C. Sinico, F. Marongiu, G. Ennas and A. M. Fadda
18

140 PLATELET LYSATE AND MANUKA HONEY COMPONENTS LOADED IN PECTIN PARTICLES
FOR THE TREATMENT OF CHRONIC SKIN ULCERS
M. Tenci, S. Rossi, F. Ferrari, M. Daglia, A. Di Lorenzo, M. C. Bonferoni, G. Sandri, M. Mori,
C. Boselli and C. Caramella
141 Pluronic F127 micellar carriers for topical acne treatment
S. Gngr
142 Preparation and characterization of topical hydrogel containing nanonized
papaverine hydrochloride
S. Berk, R. Ambrus, G. Dek, P. Szab-Rvsz, L. Pajor and E. Csnyi
143 PREPARATION AND EVALUATION OF COLLAGEN-LAMININ DERMAL MATRIX
IMPREGNATED WTH RESVERATROL MICROPARTICLES
E. H. GOKCE, I. EROGLU, N. TSAPIS, S. TUNCAY-TANRIVERDI, G. GOKCE, E. FATTAL and O. OZER
144 Preparation, characterization and long-term stability evaluation of O/W cream
containing coenzyme Q10-loaded nanoemulsion in galenical laboratory conditions
N. Dragicevic-Curic, J. Bjeletic, B. Vucelic and M. Bajcic
145 Quercetin smartCrystals: production, antioxidant activity, and physical stability
in nonionic gels
T. Hatahet, M. Morille, A. Hommoss, R. Muller and S. Bgu
146 Release profile and antioxidant activity evaluation of a topical gel enriched with
bioactive extract from grape pomace
M. Allegro, J. Marto, C. Montoya, N. Oliveira, S. Gonalves, A. Paiva, S. Barreiros, P. Simes,
L. Gonalves and H. Ribeiro
147 Silicone Pressure Sensitive Adhesive as a topical cream
M. Le Meur, L. Marteaux, F. Galeone, X. Thomas, H. Aliyar, L. Maes and M. Eeman
148 SKIN ADAPTED AGAR DIFFUSION ANTIBIOGRAM AS IN-VITRO PHARMACODYNAMIC
EQUIVALENCE MODEL
M. Sacha, A. Fargier and E. Haltner
149 smartPearls/SYLOID 3D - superior generation of dermal delivery systems based on
amorphous actives/drugs
R. H. Mller, F. Monsuur, H. H. Hfer and C. M. Keck
150 Starch nanocapsules as potential carriers for topical delivery of hydrophobic drugs
J. Marto, L. Gouveia, L. Gonalves, E. Oliveira, H. Ribeiro and A. Almeida
151 Starch-based Pickering emulsions containing a hydrophilic drug for topical application:
a quality by design approach
J. Marto, L. Gouveia, I. Jorge, L. Gonalves, E. Oliveira, A. Almeida and H. Ribeiro
152 STUDY OF HUMAN SKIN BIOMECHANICAL PROPERTIES AFTER TOPICAL APPLICATION
OF AN ANTIFUNGAL NANOSTRUCTURED EMULSION
C. Caadas, J. Suer, M. Mallandrich, L. Halbaut, A. M. del Pozo and A. C. Calpena
153 Sucrose esters and polysorbate 80 as co-emulsifiers in development of nanoemulsions
for improved aceclofenac skin delivery
T. Isailovic,
S. Dordevic,
M. Lukic,
I. Pantelic,
D. Randelovic,
B. Markovic and S. Savic

19
154 The effect of PAMAM-NH2 G2 and G3 on physicochemical properties of hydrogels

with erythromycin
K. Winnicka, M. Wroblewska and K. Sosnowska
Physical Pharmacy
155 Amorphous Recrystallisation to the Hydrated State: Correlation between Predictive
Thermodynamic Approaches and Real-Time Stability Studies
M. d. F. Pina, J. Pinto, J. Sousa, D. Craig and M. Zhao
156 Cerebroprotection of S-nitrosoglutathione-loaded in situ forming microparticles against
thromboembolic stroke
M. Parent, F. Dupuis, J. Perrin, C. Vigneron, N. Violle, J.-F. Bisson, I. Lartaud and A. Boudier
157 Processing induced lactose polymorphism
A. Della Bella, M. Muller, L. Soldati and R. Bettini
158 Sustained-release formulations of monoclonal antibody for subcutaneous delivery:
pK study in rats
S. Marquette, A. Yates, L. Denis, I. Langer, K. Amighi and J. Goole
159 The use of a low glass transition temperature polymer allows in situ formation of
solid dispersions
M. Doreth, K. Lbmann, H. Grohganz, R. Holm, H. Lopez de Diego, A. Mllertz, T. Rades
and P. Priemel
160 Tobramycin solid-state investigation
D. Frascio, E. Salomi, F. Martinelli, M. Di Cuia, A. G. Balducci, P. Colombo, F. Buttini and R. Bettini
161 Towards the fabrication of electrospun fibers for controlled drug release: controlling
the release kinetics by overcoming drug crystal formation
S. Seif and M. Windbergs
Preformulation
162 Influence of excipients on solvent-mediated hydrate formation of piroxicam studied
by dynamic imaging
W. Kirchmeyer, N. Wyttenbach, J. Alsenz and M. Kuentz
163 Adjusting the particle sizes of solid lipid microparticle dispersions for various drug
delivery applications
A. Lauterbach and C. C. Mller-Goymann
164 Assessment of drug-stabilizer interactions by contact angle and surface plasmon
resonance measurements
T. Viitala, S. Langeraert, A. Kartal.Hodzic, C. Vervaet, J. Hirvonen and L. Peltonen
165 Benefits of hypromellose capsules Vs. hard gelatin capsules to improve stability
hydroxy-acids based formulation: ascorbic acid case study
F. Maron
166 DEVELOPMENT AND CHARACTERIZATION OF A NEW RECTAL FORM
J. BOUYSSOU, L. GRISLAIN, P. GUEROULT, D. LARROUTURE, G. LEMAGNEN and E. VIOLET
20

167 Dissolution behavior of crystalline and quench cooled carbamazepine in biorelevant

gastric and intestinal media
L. Jensen, P. Priemel, F. Skautrup, A. Mllertz and T. Rades
168 DSC studies on water effusion as a complementary tool for drug release investigations
B. Bellich, M. Borgogna and A. Cesro
169 Effect of polymers on the stability of anhydrous olanzapine during processing
M. Paisana, M. A. Wahl and J. F. Pinto
170 Alkylamine Template Based Hexagonal Mesoporous Silica (HMS) For Dissolution
Enhancement Of fenofibrate
N. Jadhav and P. Vavia
171 Is thermodynamic solubility of tadalafil in Kollidon VA 64 the key parameter affecting
physical stability of the amorphous solid dispersion?
K. Wlodarski, W. Sawicki, L. Tajber and M. Paluch
172 Moisture sorption of granulated pyridostigmine bromide
T. Avgerinos, K. Kachrimanis, A. Avgerinos and I. Nikolakakis
173 Molecular water interaction in lipid-based formulations regarding capsule compatibility
A. Machado, T. Kokubo, R. Bravo, B. Jones, C. Scialdone, G. Dujovny and M. Kuentz
174 Pharmacokinetics evaluation of tramadol in thermoreversibles gels
G. Tofoli, J. Pedrazzoli Junior, S. A. Calafatti, D. R. de Araujo and J. Z. B. Papini
175 Production and Stabilization of Olanzapine Nanoparticles with Rapid Expansion
of Supercritical Solutions (RESS)
M. Paisana, K. Mllers, J. F. Pinto and M. A. Wahl
176 Supersaturation of zafirlukast in fasted and fed intestinal media with and without
precipitation inhibitors
C. M. Madsen, A. Mllertz and T. Rades
177 SURFACE ACTIVITY OF NOVEL SURFACE ACTIVE COMPOUNDS, PRODUCTS OF CATALYTIC
OXYETHYLATION OF CHOLIC ACID AND THEIR MICELLAR ADDUCTS WITH SELECTED
LIPOPHILIC THERAPEUTIC AGENTS
M. Kolodziejczyk, M. Nachajski, M. Lukosek and M. Zgoda
178 TABLETS WITH THE CONTENT OF CORNELIAN CHERRY (CORNUS MAS L.) PREPARED
BY DIRECT COMPRESSION
A. Franc, S. Krahujec, P. Doleel, D. Sabadkov and J. Muselk
Protein Formulation & Aggregation

179 In vivo evaluation of rh-insulin loaded microemulsion as oral delivery system
G. Erel, M. Kotmaki, S. Szer Karadagli
and A. G. Kantarci
180 Novel in vitro instrument for estimating formulation performance of subcutaneously
administered therapeutics
H. Kinnunen, K. Box and R. Mrsny
181 The Use of SAXS for Screening the Dissolution Behavior of Lyophilized Protein
V. Wahl, E.-M. Saurugger, J. Khinast and P. Laggner
21
Gene Delivery
182 Cationic Polyaspartamide as siRNA delivery systems for down regulation of a
proinflammatory cytokine
S. Di Gioia, C. Sardo, D. Triolo, G. Belgiovine, S. Castellani, M. Conese, G. Giammona and
G. Cavallaro
183 Development of non-toxic, cationic lipid coated, magnetic nanoparticles (MNPs) for gene
delivery with a novel method
H. Akbaba, U. Karagz, Y. Selamet and A. G. Kantarci
184 IN VIVO ELECTROPORATION: A VERSATILE AND MULTITASK TECHNOLOGY TO
FIGHT CANCER
E. Marra
185 Lipid Nanoparticles Formulated with HM-Chitosan for siRNA Delivery
O. Tezgel, A. Szarpak-Jankowska, R. Auzly-Velty, F. Navarro and I. Texier-Nogues
186 Mucoadhesive hydroxyethyl-cellulose sponges as lipoplexes delivery system for
vaginal application
T. Furst, A. Lechanteur, B. Evrard and G. Piel
187 Polyplex based on polycarbonate polymers for an efficient delivery of HDAC5
and HDAC7 siRNA
A. Frre, S. Tempelaar, B. Evrard, O. Peulen, L. Mespouille, D. Mottet and G. Piel
Miscellaneous
188 Development of hydrogel-formulations containing local anesthetics in poly
(-caprolactone) nanocapsules for topical oral application.
M. Franz-Montan, C. B. da Silva, S. d. C. Santos, B. V. Muniz, C. M. G. da Silva, E. de Paul,
M. C. Volpato, F. C. Groppo and L. F. Fraceto
189 Influence of Papp values on prediction of plasma levels by in silico modeling of
inhalation products
S. Salar-Behzadi, C. Meindl, S. Stranzinger, N. Dzidic, S. Mohr, S. Wu, A. Mercuri and E. Frhlich
190 Jet coating for the development of drug eluting stents
N. Scoutaris, F. Chai, B. Maurel, J. Sobocinski, M. Zhao, J. Moffat, D. Craig, N. Blanchemain
and D. Douroumis
191 Clinical analysis of Paclitaxel Eluting Stent compared with Simvastatin Eluting Stent,
coated by means of inkjet printing technology
N. Scoutaris, F. Chai, B. Maurel, J. Sobocinski, M. Zhao, J. Moffat, D. Craig, N. Blanchemain
and D. Douroumis
192 ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF CURCUMIN BY EUDRAGIT
EPO-BASED SOLID DISPERSIONS PREPARED BY HOT MELT EXTRUSION AND SPRAY
DRYING TECHNOLOGY
A. Gangurde, S. Javeer, J. Pawae, D. Jaiswar and P. Amin
193 Formulation of magnetic siRNA nanovectors (MSN) as a promising theranostic tool
for (breast) cancer
S. David, H. Marchais, D. Bedin and I. Chourpa
22


Posters
Exhibited continuously from 9:00 to 17:00, with special sessions from 12:30 to 15:00.
The number indicates the number displayed on the poster panel.
Bioavailability & Absorption Enhancement

1
Biphasic dissolution studies: Impact of concentration and particle size on partition rate
J. Comer, K. Box and R. Taylor
Co-Crystals and Their Advantages for Life Cycle Management of APIs with
Difficult Properties
M. Viertelhaus, A. Hafner, T. Chiodo, T. Hintermann and M. Vossen
Effect of organic solvents on the recrystallization behavior of amorphous solid

dispersions prepared by spray drying
C. Marschall, R. Maurer and S. Page
Lipid Based Capsule Products to Increase Bioavailability and Reduce Food Effect for
a Poorly Soluble Compound
A. IGONIN, J. MENSCH, S. INGHELBRECHT, J. CEULEMANS, H. VERMEERSCH, H. BENAMEUR
and J. VERTOMMEN
Optimization of a PGSS manufacturing process of lipid-based solid dispersion containing

fenofibrate
A. Pestieau, F. Krier, P. Lebrun and B. Evrard
Pharmacokinetics of pro-pheroid formulated amodiaquine

A. Grobler, L. Gibhard, C. Masimirembwa and R. Thelingwani
Preparation and Characterization of Nano Suspension of Poorly Soluble Drugs using

Hydroxypropyl Cellulose (HPC)
S. Kodama, K. Sugisawa, B. Ehlig, R. Fukuda, T. Andoh and H. Ichikawa
Production of amorphous nano-solid dispersions using a solvent controlled

precipitation process
. Duarte, R. Pereira, J. Vicente, J. F. Pinto and M. Temtem
Scale-up Transition from Spray Drying to HME with AFFINISOL HPMC HME
W. Porter III, O. Kevin, S. Wes and S. Uma
10
Study of the synergic effect of naringenin and quercetin in their permeability and
metabolic fate
N. Orrego-Lagarn, M. Martnez-Huelamo, M. R. Lamuela-Ravents and E. Escribano
11
Supersaturation, phase separation and the measurement of drug precipitation rates

J. Comer, K. Box and R. Taylor
12
Transbuccal delivery of semi-solid formulations containing doxepin: ex vivo and in

vivo evaluation
R. Sanz, B. Clares, M. Mallandrich and A. C. Calpena

23
Buccal & Nasal Delivery

13
Chitosan particulate delivery system for intranasal influenza DNA vaccine

C. Sawaengsak, Y. Mori, K. Yamanishi, W. Chaicumpa and N. Sinchaipanid
14
Composite hydroxylpropylmethylcellulose based films and wafers for buccal

drug delivery
O. Okeke and J. Boateng
15
CORRELATION BETWEEN DISSOLUTION AND BUCCAL PERMEATION OF KETOPROFEN

ORODISPERSIBLE FILMS
M. Sacha, A. Fargier, R. Krampe, D. Sieber, P. Kleinbudde, J. Breitkreutz and E. Haltner
16
Fillet: A New Dosage Form Combining Orodispersible Films and Orodispersible Tablets
- Influence of Different Films and Tablets R. Krampe, D. Sieber, C. Stolze, V. Lenhart, M. Preis and J. Breitkreutz
17
Fillet: A New Dosage Form Combining Orodispersible Films and Orodispersible Tablets
- Preparation concepts D. Sieber, R. Krampe, C. Stolze, V. Lenhart, M. Preis and J. Breitkreutz
18
In vitro permeability study of betahistine dihydrochloride delivered by bioadhesive

microspheres intended for nasal drug delivery
B. Pilicheva, M. Draganova-Filipova, P. Zagorchev and M. Kassarova
19
In-Vitro Models Simulating Buccal Tissue in the Oral Cavity

C. Schimpel, B. Teubl, E. Frhlich and E. Roblegg
20
Intranasal delivery of anti-Galectin-1 formulation to increase the efficiency of

chemo- and immunotherapy for glioblastoma
M. Van Woensel, N. Wauthoz, R. Rosiere, K. Amighi, V. Mathieu, F. Lefranc, S. Van Gool,
T. Mathivet and S. De Vleeschouwer
21
Oromucosal film preparations for peptides - Points to consider

S. Lindert, M. Pein, F. K. Hansen and J. Breitkreutz
22
Whey proteins: a promising excipient to promote oral drug delivery and permeability
H. Hsein, V. Hoffart, G. Garrait, E. Dat-Lain and E. Beyssac
Nanoparticles & Vesicles

23
A Novel Oxalipatin Derivative Showed Enhanced Efficacy in an Orthotopic Model of

Ovarian Cancer
A. Abu Ammar, T. Nassar, D. Gibson and S. Benita
24
A PROCESS FOR PREPARATION OF ULTRASMALL CURCUMIN NANOPARTICLES

R. Kalhapure, S. Sonawane and T. Govender
25
Aminodextran-coated magnetic nanoparticles as a new hyperthermia approach

M. K. Lima Tenrio, E. Alfonso Gmez Pineda, H. Fessi and A. Elaissari
24

26
Ammonium glycyrrhizinate-loaded niosomes as potential nanotherapeutics for

inflammation: a comparative study
C. Marianecci, F. Rinaldi, C. Ingallina, P. N. Hanieh, D. Paolino, C. Celia, F. Cilurzo, S. Pieretti
and M. Carafa
27
Amorphous Flubendazole Dispersed in Electrospun Nanofibers: Bioavailability in the

Rat and Tablet Formation
G. Verreck, I. Van Assche, C. Mackie, P. Boeykens, M. E. Brewster, Z. K. Nagy, T. Vigh, A. Balogh
and G. Marosi
28
Antibiofilm activity of Melaleuca alternifolia nanoparticles

M. Ebling de Souza, R. de Almeida Vaucher, L. Quintana Lopes, R. Raffin, D. Martinez Stefani,
R. Christ Vianna Santos and P. Gomes
29
Antidepressant-like activity of liposomal formulation containing nimodipine treatment

in the tail suspension and forced swim test in mice
L. C. G. e A. I. Moreno, J. M. Irache, R. M. Freitas and N. S. Santos Magalhes
30
Arsenic loaded anti-GD2 immunoliposomes: Design and in vitro targeting to

neuroblastoma cells
H. Deibel and R. Schubert
31
Aspherical Nanoparticles for Drug Delivery Application

A. Castoldi, P. Dersch, S. Gordon and C.-M. Lehr
32
Biocompatibilization of micelles by hyaluronan

T. Pilgrov and M. Peka r
33
Biocompatible nanoparticles and gadolinium chelates: towards new hypersensitive

MRI contrast agents
M. Callewaert, V. G. Roullin, Y. Belabassi, C. Cadiou, C. Portefaix, S. Laurent, L. Vander Elst,
M. Molinari, F. Chuburu and M.-C. Andry
34
Biological evaluation of liposomes containing 6BrCaQ, a C-terminal Hsp90 inhibitor,

for prostate cancer treatment
F. Sauvage, S. Franze, S. Messaoudi, M. Alami, S. Lesieur, F.-X. Legrand, E. Fattal, G. Barratt
and J. Vergnaud-Gauduchon
35
Carbohydrate Ligand Anchored Nanoparticles with Improved Efficacy in the

Fibrosarcoma Tumor Model
S. Pranatharthiharan and P. Devarajan
36
Cardiovascular risk potential of PLGA-PEG nanoparticles used in drug delivery and

targeting
R. Bakhaidar, S. O'Neill and Z. Ramtoola
37
Cationic nanoparticles. An analytical approach to biological relevance

R. Gossmann, M. Hummel, D. Mulac, J. Brockmeyer and K. Langer
38
Cholesterol Free Pegylated Liposomes: A Potential for Brain Targeting

P. Wavikar and P. Vavia
39
Co-encapsulating lipid nanoparticles for transdermal and oral delivery

M. Mendes, C. Vitorino, J. Sousa and A. Pais

25
40
Comparison of different nanonization approaches for -carotene

P. Scholz, S. Lohan, M. C. Meinke, R. H. Mller and C. M. Keck
41
Comparison of m-PEG-PCL polymersomes size measurements by 3 optical techniques:

DLS, NTA and two-photon microscopy
M. Inkichari, C.-H. Brachais, C. Bouvier, A. Assifaoui, P. Winckler, R. Seigneuric, S. Auguste
and O. Chambin
42
Cyclosporin smartPearls for improved topical delivery

S. Staufenbiel, G. B. Romero, N. Jin, C. M. Keck and R. H. Mller
43
Design of new nanoparticles as tools for CNS disease diagnosis

E. Teston, Y. Hamdous, C. Chuon, J. Seguin, C. Marie, T. Maldiney, B. T. Doan, N. Mignet,
C. Richard and K. Andrieux
44
DESIGN OF POLYMERIC NANOFIBER DIAMETER, DRUG LOADING AND RELEASE

J. Kristl, . Zupansi s,
P. Kocbek and S. Baumgartner
45
Development and characterization of piroxicam loaded nanospheres to enhance the

solubility and bioavailability adopting electrospraying technique
O. Mustapha, F.-U.-. Din, A. Yousaf, D. W. Kim, R. Rashid, J. H. Park, T. Ramasay, J. O. Kim,
C. S. Yong and H.-G. Choi
46
Electrospun cyclodextrin-based formulation of aripiprazole and its in vitro

dissolution-absorption testing using micro-FluxTM
G. Marosi, E. Borbas, Z. Nagy, A. Balogh and B. Sinko
47
Development of novel solid lipid nanoparticles-loaded dual-reverse thermosensitive

nanomicelle with improved bioavailability and reduced toxicity
F. Din, O. Mustapha, A. Yousaf, D. W. Kim, R. Rashid, J. H. Park, T. Ramasamy, J. O. Kim,
C. S. Yong and H.-G. Choi
48
Development, evaluation and mathematical modeling of insulin release from chitosan

and chitosan derivatives nanoparticles
J. Hecq, F. Siepmann, J. Siepmann, K. Amighi and J. Goole
49
Dexamethasone nanocrystals for improved ocular delivery

G. Bahu Romero, C. M. Keck, N. Bou-Chacra and R. H. Mller
50
Effect of ionic strength on the formation of fluoride loaded pectin nanoparticles

for dental delivery
S. Nguyen, S. Pistone, C. Claudio, G. Smistad and M. Hiorth
51
Effects of suberin fatty acids on the formation and physical stability of medicated
nanofibers intended for wound healing
I. Tamm, L. Rammo, I. Laidme, U. Paaver, K. Kirsime, N. Skalko-Basnet, A. Halenius, J. Yliruusi,
J. Heinmki and K. Kogermann
52
Encapsulation efficiency of a drug into a nanosize carrier & amp; assessment of

nanoparticle stability in a complex liquid matrix: Two working examples of NTA
characterization
P. PEOTTA, P. HOLE, B. CARR and P. VINCENT
53
Encapsulation of dexamethasone palmitate into PLGA-PEG nanoparticles

R. Simn-Vzquez, N. Tsapis and E. Fattal
26

54
Enhancing Vancomycin Delivery via Lipid-Polymer Hybrid Nanoparticles

N. Seedat, R. Kalhapure, C. Mocktar and T. Govender
55
Evaluation of biodegradability of novel polymeric nanoparticles based on amphiphilic

polylactide-polyaspartamide derivatives
B. Porsio, E. F. Craparo, D. Triolo, G. Giammona and G. Cavallaro
56
Evaluation of Chitosan Nanoparticles for Intravesical Administration of Gemcitabine HCl

for the Treatment of Superficial Bladder Cancer
Z. Ay S enyigit,
D. Ilem zdemir, S. Y. Karavana, . aliskan, S. S en and E. Baloglu
57
Evaluation of cytotoxicity of Geranium oil-loaded nanoemulsions

J. Giongo, R. Vaucher, A. Ourique, M. Steffler, M. Sagrillo, P. Gomes and M. Steppe
58
Exploring drug release from magnetic nanocarriers by low-level magnetic stimulation

R. Spera, F. Apollonio, M. Liberti, M. A. Casadei, C. Merla, R. Pinto and S. Petralito
59
Factorial design-aided development of salicylic acid loaded-nanostructured lipid carriers

B. Sto, N. Ungvri, E. Csnyi, P. Szab Rvsz and S. Berk
60
Feasibility of encapsulation dihydromyricetin in cationic nanocapsules

A. J. Figueir Dalcin, A. Ferreira Ourique, R. Platcheck Raffin, R. Christ Vianna Santos
and P. Gomes
61
Flavanones: Cytotoxic activity and release study of nanoestructured emulsion

B. Andrade, C. Caadas, M. Mallandrich, V. No, B. Clares, A. Calpena, M. L. Garca
and M. L. Garduo
62
Formation and stability of curcumin nanoemulsions prepared by phase inversion

temperature method
A. Jintapattanakit, R. Leam-or, S. Maneejansook and V. Junyaprasert
63
FORMULATING LINOLEIC ACID AS A NANOEMULSION ENHANCES ITS

ANTIMICROBIAL ACTIVITY
S. Sonawane, C. Mocktar, R. Kalhapure and T. Govender
64
Formulation and In Vitro Evaluation of Furosemide Nanosuspensions

T. Glsn Inal, S. Ebadi Borna, I. Vural and S. Sahin
65
Formulation and stability evaluation of novel antimicrobial nanofibrous wound dressings

U. Paaver, I. Tamm, A. Toom, I. Laidme, A. Meos, K. Kirsime, N. Skalko-Basnet, J. Heinmki
and K. Kogermann
66
Gemcitabine-squalene nanoparticles: involvement of plasma lipoproteins in the

therapeutic response
D. Sobot, S. Mura, L. Dalbin, S. Lepetre and P. Couvreur
67
Human Serum Albumin (HSA) nanoparticles stabilized by polymer coating for the
delivery of suramin
I. Luis de Redin, M. Ageros, J. M. Llabot, C. Boiero and J. M. Irache
68
PHB based microparticles for ivermectin sustained release

E. Engasheva, S. Yakovlev, A. Zernov, A. Bonartsev, G. Bonartseva, E. Daugalieva, K. Shaitan
and S. Engashev

27
69
In vitro behaviour of hybrid lipid/chitosan nanoparticles for the oral delivery of heparin
F. Sacchetti, R. Aracri, E. Maretti, V. Iannuccelli, M. Montanari, B. Pavan, A. Dalpiaz and E. Leo
70
In Vitro Release and In Vivo Tolerance of Pranoprofen-Loaded Nanoparticles Hydrogel

B. Guevara Granados, G. Abrego Escobar, M. L. Garca Lopez and A. C. Calpena Campmany
71
Influence of colloidal lipid carrier matrix on fenofibrate loading capacity a passive

loading approach
K. Gke and H. Bunjes
72
Influence of polymer end-chemistry on the morphology of perfluorohexane polymeric

microcapsules intended as ultrasound contrast agents
L. Mousnier, N. Huang, E. Morvan, E. Fattal and N. Tsapis
73
Investigating the influence of glass transition temperature on the release behaviour of

flurbiprofen- and mTHPP-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles
S. Lappe and K. Langer
74
Investigation of titanate nanotube-API composites as promising drug delivery systems

B. Sipos, T. Sovny, A. Spi, Z. Knya, K. Pintye-Hdi and G. Regdon jr.
75
LABELING EFFICIENCY AND CELL BINDING of 99mTc LABELED CHITOSAN NANOPARTICLES

E. Gundogdu, D. Ilem Ozdemir, M. Ekinci, E. Ozgenc and M. Asikoglu
76
Layer-by-layer nanoencapsulation of paclitaxel

A. Polomska, H. Merten, A. Plckthun, M.-A. Gauthier and J.-C. Leroux
77
LIPOSOME CONTAINING ESTETROL FOR THE TREATMENT OF ISCHEMIA DISEASES

IN PREMATURE BABIES
C. Palazzo, R. Karim, M. Mawet, C. Maillard, J.-M. Foidart, B. Evrard and G. Piel
78
LIPOSOMES AS CARRIERS OF LIPID SOLUBLE ANTIOXIDANTS- RESVERATROL IN

PRESENCE OF VITAMIN E
V. KENCHAPPA, M. WAHL, L. BUKARICA, J. CEVIC and H. HEINLE
79
Loading of Aloe-Emodin in gemini based cationic liposomes by the acetate

gradient method
C. Bombelli, C. Giuliani, B. Altieri, G. Mancini, L. Galantini, A. Stringaro and M. Colone
80
Manufacture of Perfluorocarbon-Nanoemulsions for site specific targeting of activated

platelets via a single-chain variable fragment binding to glycoprotein IIb/IIIa
C. Grapentin and R. Schubert
81
MIL100 nanoparticles as a Busulfan delivery system

T. Simon-Yarza, L. L. Lesuer, A. Seck, T. Baati, M. Chiper, A. Paci, P. Couvreur, C. Serre, R. Gref
and P. Horcajada
82
NLC and nanocrystal combination for effective treatment of couperosis

S. M. Pyo, G. B. Romero, M. Meinke, A. Klein, T. C. Fischer, C. M. Keck and R. H. Mller
83
Novel Approaches for Gelatin Nanoparticle Preparation

K. Geh, M. Hubert and G. Winter
28

84
Novel formulations for mitochondrial delivery based on alkylphosphonium

bolaamphiphiles
F. Ceccacci, C. Bombelli, S. Sennato, E. Rossi, S. Gallina, B. Altieri, V. Moresi, E. Pigna
and M. Diociaiuti
85
OLEIC ACID DERIVED HETEROLIPID BASED SMEDDS ENHANCE THE AQUEOUS SOLUBILITY
OF CURCUMIN
R. Kalhapure, D. Sikwal and T. Govender
86
Optimization of the production of curcumin liposomes by ultrasonication based on

Pharmaceutical Quality by Design approach
A. R. Bilia, F. Mazzacuva, C. Guccione and M. C. Bergonzi
87
PEGylated liposomes containing apigenin for the treatment of glioblastoma

R. Karim, C. Palazzo, N. Dubois, V. Bours, C. Passirani and G. Piel
88
Peptide-functionalized Nanoparticles for Selective Targeting of Pancreatic Tumor

S. MURA, S. VALETTI, F. MAIONE, D. DESMAELE, M. NOIRAY, J. VERGNAUD, C. VAUTHIER,
L. CATTEL, E. GIRAUDO and P. COUVREUR
89
pH sensitive PEGylated Liposomes delivering active hydrophilic peptide with anticancer

activity: in vitro study on cDDP-resistant ovarian cell line
F. Sacchetti, C. Marraccini, D. D'Arca, D. Pinetti, F. Genovese, E. Maretti, V. Iannuccelli,
M. P. Costi and E. Leo
90
Physicochemical Stability and Corneal Permeation of Pranoprofen-Loaded Nanoparticles

Based Hydrogel
G. Abrego Escobar, H. Alvarado Bonilla, B. Guevara Granados, A. C. Calpena Campmany
and M. L. Garcia Lopez
91
Pigs scleral permeation by freeze drying carprofen nanoparticles

A. Parra, M. Mallandrich, H. L. Alvarado, B. Clares, M. L. Garca and A. C. Calpena
92
Poly(ethylene glycol)-cholesterol molecules for liposomal surface modification via the

sterol-based post-insertion technique (SPIT) and their behavior towards acceptor media
D. Molnar
93
Poly-L-Lysine-coated liposomes as potential delivery systems for treatment of diabetic

vascular diseases.
M. L. Manca, D. Valenti, F. Marongiu, M. Manconi, G. Brotzu and A. M. Fadda
94
Polysaccharide-based nanohydrogel systems for drug delivery applications

P. Matricardi, C. Di Meo, E. Montanari, C. Cencetti, S. Laserra, G. Manzi, T. Coviello
and F. Alhaique
95
Preformulation study of liposomes as nanosized drug delivery systems

In vitro drug transport.
K. Dr, J. Malth, P. Hegyi, P. Szab-Rvsz and P. Sipos
96
Preparation and Pharmaceutical Evaluation of Nano-fiber Matrix Supported Drug

Delivery System using the Solvent-Based Electrospinning Method
M. Hamori, K. Yoshida, K. Nagano, S. Kakimoto, A. Nishimura, K. Naruhashi and N. Shibata
97
Preparation of liposomes with asymmetric bilayers produced from nanoemulsions in

a centrifugal field
J.-H. Sommerling, M. de Matos, E. Hildebrandt, G. Leneweit and H. Nirschl

29
98
Preparation of New Nanovectors from Biomass: Chemo-Enzymatic Synthesis of

Glycerolipidyl-Cyclodextrins and study of drug encapsulation
V. Bonnet, Y. Miao, A. Furlan and C. Sarazin
99
Preparation of submicron magnetic latex particles for biomedical applications:

Morphology control
E. Taveira Tenrio-Neto, T. Jamshaid, N. Zine, A. Errachid El-Salhi, M. Hiroiuqui Kunita,
H. Fessi and A. Elaissari
100 Production of chitosan nanoparticles as matrix to sustain drug release across orally
disintegrating tablets with the aid of design of experiment to optimize conditions
A. Matoug-Elwerfalli and A. El-shaer
101 Protective effect of curcumin-loaded new polymer-glycerosome systems on
pulmonary diseases.
M. L. Manca, I. Castangia, C. Caddeo, M. C. Cardia, M. Manconi, C. Sinico and A. M. Fadda
102 Remote loading of Voacamine in cationic liposomes for the treatment of
osteosarcoma resistant cell lines
L. Giansanti, B. Altieri, M. Condello, E. Pellegrini, G. Mancini and S. Meschini
103 smartCrystals for functional foods: BIOSMARTS
G. Bahu Romero, C. M. Keck, E. Brysch, W. Brysch and R. H. Mller
104 smartLipids the smarter Nanostructured Lipid Carriers (NLC)
R. H. Mller, R. Ruick and C. M. Keck
105 The Use of Excited-State Proton Transfer in Observation of The Interaction of Potential
Hyaluronan-Surfactant Drug Nanocarriers
J. Mondek and M. Pekar
106 Thermoresponsive mesoporous silica nanoparticles as a topical delivery system for
antioxidants
S. Sapino, E. Ugazio, L. Gastaldi, S. A. Jadhav, V. Brunella, D. Scalarone, I. Miletto and G. Berlier
107 Transcorneal delivery of PLGA-based nanoparticles of Ketorolac
M. Mallandrich, A. Calpena, A. Parra, M. L. Garcia and F. Fernndez-Campos
108 Use of Lipid Nanocapsules for air bubbles stabilization
C. R. A. MOUZOUVI, P. SAULNIER and A. BIGOT
109 Verbascoside loaded in liposomes: increased stability and prolonged antineuropathic and
antiinflammatory activities
A. R. Bilia, B. Isacchi, M. C. Bergonzi, C. Ghelardini and N. Galeotti
110 ZnO-based Quantum Dots for biological applications
E. Berbel Manaia, B. Caetano, V. Briois, R. Kiatkoski Kaminski, L. Chiavacci and C. Bourgaux
Transdermal Delivery
111 Aceclofenac loaded bicontinuous microemulsions: in vitro release, tape stripping
and pharmacokinetic study
M. Todosijevic, V. Savic, M. Savic, D. Randelovic, M. Gaperlin, B. Batinic, T. Isailovic,
B. Markovic and S. Savic
30

112 Captisol as Dermal Penetration Enhancer for Lipophilic Drugs

A. Juluri and N. Murthy
113 Early preclinical evaluation of transdermal druglikeness - a case study with selective
androgen receptor modulators
T. Ullrich, H. Keller, S. Weiler and P. G. Santos
114 Hydrogels of carboxymethyl scleroglucan: a smart biocompatible system for
topical formulations
P. Paolicelli, S. Pacelli, S. Petralito, A. Adrover and M. A. Casadei
115 In vitro and ex vivo evaluation of a ready to use transdermal vehicle for the permeation
of ondansetron
F. BOURDON, M. LECOEUR, P. ODOU, C. VACCHER and C. FOULON
116 Influence of formulation polarity on transdermal delivery by implementation of the
delivery gap principle
M. Gerber, C. Burger, J. Du Preez and J. Du Plessis
117 Investigation of microemulsion microstructure and its impact on skin delivery of
flufenamic acid
D. Mahrhauser, H. Khlig, E. Partyka Jankowska, K. Kwizda and C. Valenta
118 Macromolecules penetration in irritant contact dermatitis
M. Abdel-Mottaleb, A. Bduneau, Y. Pellequer and A. Lamprecht
119 Microrheological study of hyaluronan based system for dermal delivery applications
Z. Hnyluchov and M. Pekar
120 Modified Chitosan sponges as antibacterial agents
P. Siafaka and D. BIkiaris
121 Non-invasive in vivo comparison of penetration enhancers containing hydrogel
formulations
B. Balzs, M. Bakonyi, S. Berk, M. Budai-Szucs and E. Csnyi
122 Optimization of microemulsion composition applying experimental planning
V. Jukait, M. ilius, K. Ramanauskien and V. Briedis
123 PDT(Photo Dynamic Therapy) using LPC (Lysophosphatidylcholines) and the photosensitizer chlorine- derivatives useful for Trichophyton rubrum
Y. Woo, Y. Park, H. Ji, J. Kim, S. Jo and H. Yu
124 Physical characterization and release of a silver sulfadizine-chitosan hydrogel for
wound treatment
R. d. O. Batista, G. d. S. Nascimento, L. M. Verssimo, P. S. H. Picciani, K. G. d. H. Silva
and F. Reynaud
125 Preparation and characterization of alcohol-free, grapefruit oil base microemulsions
N. Jaipakdee and E. Limpongsa
126 smartPearls - stability and performance in topical gels
N. Jin, S. Staufenbiel, C. Keck and R. Mller
127 The impact of low molecular weight polysiloxanes on the skin barrier
K. Mojsiewicz-Pienkowska, K. Szymkowska, D. Glamowska, K. Cal and Z. Jankowski

31
128 Thermal Analysis of Stratum Corneum using Modulated Temperature Differential

Scanning Calorimetry (MTDSC)
C. F. Goh, D. Craig, J. Hadgraft and M. Lane
129 Topical delivery of lidocaine and prilocaine with the use of Pheroid technology
J. Du Plessis, D. Nell, J. Du Preez and M. Gerber
130 Transdermal iontophoretic delivery of propofol (CAPTISOL-enabled Complex);
plasma and brain pharmacokinetic study
A. Juluri, N. Murthy and P. Manda
Parenteral Delivery
131 Development of an Ex-Vivo Pig Skin Model to Determine Mechanistic Effects of Antibody
Formulations Following Subcutaneous Injection
S. Eichling, C. Jahn, A. Popp, W. Frie and G. Fricker
132 Indocyanine green-loaded chitosan/alginate microparticles for transcatheter arterial
embolization (TAE) in hepatocellular carcinoma (HCC)
E. P. Porcu, A. Salis, G. Rassu, E. Gavini, P. Dionigi, M. Maestri and P. Giunchedi
133 Investigation of a flow through cell adapter for dissolution testing of an intramuscular
applied aqueous solution and an oily suspension
M. Probst, M. Schmidt, E. Noll, A. Seidlitz and W. Weitschies
134 Is poloxamer 188 desorbed from the trimyristin nanoparticle interface upon dilution?
A DSC study
E. Roese and H. Bunjes
135 Monitoring of size changes of single PLGA-microparticles and comparison with
drug release
H. Gasmi, J. Siepmann and F. Siepmann
136 Nanostructured Lipid Carriers (NLC) of Artemether-Lumefantrine combination for
intravenous malaria therapy
P. Prabhu, M. Joshi, S. Pathak, S. Sharma and V. Patravale
137 Parenteral nanoemulsions for risperidone brain delivery: design, characterization and
in vivo evaluation
S. Dordevic, T. Isailovic, N. Cekic, M. Savic, S. Savic, D. Randelovic and S. Savic
138 Progress in Complex Parenteral Formulations for the Delivery of Biopharmaceuticals and
Small Molecules Microencapsulation Scale Up and Product Enhancements
T. Tice, K. Burton, J. Atkinson, P. Markland and G. Winchester
Pediatric & Geriatric Drug Delivery

139 A novel versatile gastro-resistant paediatric formulation based on Omeprazole/SBA-15
loaded in alginate beads by prilling
P. Del Gaudio, F. De Cicco, S. Giovagnoli, M. Ricci and R. P. Aquino
32

140 An in vivo taste assessment method for the optimisation of taste-masking formulations:
the rat brief-access taste aversion (BATA) model
J. Soto, R. Turner, S. Desset-Brthes, G. Winzenburg, M. Orlu Gul and C. Tuleu
141 Anti-CD19-Targeting of Doxorubicin Liposomes for an Improved Treatment of Pediatric
Acute Lymphoblastic Leukemia
K. Zfle and R. Schubert
142 Development and Characterization of Orodispersible Mini-tablets Manufactured
by Direct Compression
M. Mnster, C. Pfeifer and J. Breitkreutz
143 Development of aged cell culture model to assess the in vitro fate of drug delivery
systems for older patients
I. Espadas Garcia, S. Hanning, M. Bunc, J. M. Prieto-Garcia and M. Orlu-Gul
144 Development of casein micellar pediatric formulations
M. Brachkova, J. T. Pinto, A. I. Fernandes and J. F. Pinto
145 Development of extended release Compritol 888 mini matrix tablets for geriatric
administration
R. Grybos, L. Freerks, Y. Rosiaux, D. Marchaud and S. Klein
146 Evaluation of the ability of powdered milk to produce mini-tablets containing
paracetamol
J. T. Pinto, M. Brachkova, A. I. Fernandes and J. F. Pinto
147 Formulation of orodispersible films for children
Z. Senta-Loys, S. Bourgeois, S. Brianon and H. Fessi
148 Hot melt coating - taste-masked multiparticulate drug delivery systems with immediate
drug release
A. Zimmer, K. Becker and S. Salar-Behzadi
149 In situ preparation of microcapsules with ethylcellulose and polyacrylate shells
incorporated in a lyophilized matrix
K. Hoppe and M. Sznitowska
150 Multiparticulate extended release dosage form for pediatric use development and
characterization
M. E. Martinez Teran, S. Mangalaboyi and M.-P. Flament
151 Orally Disintegrating Tablet Preparation by Dry Granulation Method Using Super Fine
Powder, Special Low Viscosity Hydroxypropyl Cellulose
K. Sugisawa, S. Kodama, S. Tsue, B. Ehlig, Y. Takeuchi and H. Takeuchi
152 Patient centric and age appropriate drug product design: Theory biased and
evidence based
S. Stegemann, R. Becker, R. Messina and D. van Riet-Nales
Pharmaceutical Manufacturing & Engineering

153 Comparison of a novel aerodynamic dry granulation method and conventional slugging
method in preparation of granules and tablets
A. Penkina, T. Saarinen, O. Antikainen, A. Lust, K. Kogermann, J. Yliruusi and J. Heinmki
33
154 Continuous manufacturing of delta mannitol via spray drying

V. Vanhoorne, P.-J. Van Bockstal, B. Van Snick, P. Gomes, T. De Beer, J.-P. Remon and C. Vervaet
155 Evaluating the validity of the Unified Theory of Compaction using sodium chloride
and ammonium sulphate tablets
M. Gamlen, T. Uddin and L. Martini
156 Evaluating Youngs Modulus from diametral compression data
M. Gamlen, H. Dhaliwal and L. Martini
157 Evaluation of binders for dry granulation
M. Kirsolak, H. Mangal and P. Kleinebudde
158 Co-Extrusion as innovative method for Pharmaceutics
K. Paulsen, I. Ruff and D. Leister
159 Improved Spray Drying Capability with AFFINISOL HPMCAS and HPMC High
Productivity Polymers
W. Porter III, K. ODonnell, B. Schmitt, M. Brackhagen, M. Sprehe, M. Knarr and W. Spaulding
160 Influence of different drying conditions on mono- and double-layer orodispersible films
during continuous manufacturing
Y. Thabet and J. Breitkreutz
161 Interaction of emulsifier and membrane material during the preparation of
nanoemulsions by premix membrane emulsification
S. Gehrmann and H. Bunjes
162 NANEX: Process design with potential matrix materials
R. Baumgartner, J. G. Khinast and E. Roblegg
163 Production of Dexpanthenol Loaded Polyethylene Oxide Nanofiber Mats for
Wound Healing
E. Azizoglu, C. elik, S. Tuncay Tanriverdi and . zer
164 Production, stability and downstream processing of high speed electrospun amorphous
solid dispersion of itraconazole
Z. K. Nagy, B. Dmuth, A. Balogh, H. Pataki, E. Borbs, G. Marosi, I. V. Assche and G. Verreck
165 Small Scale Twin-Screw Extrusion - Evaluation of Continuous Split Feeding in Wet
Extrusion/Spheronization
C. Mhlenfeld, D. Ghanam, J. Schwarz and M. Thommes
166 Tablet strength related to adhesion forces of tablet components measured at
the nanoscale
M. Badal Tejedor, N. Nordgren, M. Schuleit, M. W. Rutland and A. Millqvist-Fureby
167 Taguchi method used for optimization of coating process for minitablets
M. Czajkowska and M. Sznitowska
168 The Impact of Crospovidone as a Superdisintegrant for Hard Gelatin Capsule
Formulations
C. Muehlenfeld, G. Warnke, M. Opitz and S. Stegemann
34

NEED HELP TO BRING

INSOLUBLE APIS TO THE
B6G@:I4
Solving the Insoluble with Dow
Our AFFINISOL polymers are uniquely tailored to
address the solubilization performance requirements
of your APIs, whether you have chosen to formulate via
Spray-Dried Dispersion or Hot Melt Extrusion.
AFFINISOL HPMCAS, QbD sample sets offered with
expanded acetyl & succinyl levels;
NEW AFFINISOL HPMCAS High Productivity

facilitating higher throughput in spray-drying;
AFFINISOL HPMC HME, developmental

cellulosic with improved thermal properties, designed
for hot melt extrusion.
NEW
Youve invested a lot into your API. Why not

\Zii]Zbdhidjid[^i4
Explore our AFFINISOL Portfolio.
www.dowpharmasolutions.com
The DOW Diamond Logo and AFFINISOL are trademarks of The Dow Chemical Company 2014

35

La Nef
Poster Sessions and Exhibition
Amphithtre Royal
Invited talks: Transdermal Drug Delivery
09:00
Amphithtre Royal
Opening Ceremony and APGI Student Award
09:15
Amphithtre Royal
Plenary lecture: Drug Targeting - Where are we?, Patrick Couvreur
10:45

Transdermal drug delivery: A Mature and Evolving

Technology
R. Guy
Amphithtre Clovis
Short talks: Oral Controlled Drug Delivery
How does the drinking volume affect gastric dissolution in

infants? New in vitro approaches for preclinical screening
E.Kersten
Oral Delivery
Pulmonary Delivery
11:05
Dermal preparations
In-vitro dissolution testing of oral thin films (OTFs):

theory and experiments
A. Adrover
Physical Pharmacy
Preformulation
11:25
Gene Delivery
Transdermal Drug Delivery: An Industrial Viewpoint

M. Sournac
Proposal for a new dissolution method for soft

chewable delivery systems
C. Stomberg
09:00 20:00; all day
11:45
Assessing Softgel Disintegration in the Gastric Compartment:

Correlating the Dynamic Gastric Model with In Vivo
Visualization by Camera-Capsules
H. Teles
12:05
The new Guideline on Quality of Transdermal Patches: New

Requirements in Development
S. Jones
Mucoadhesive polymeric nanocomposites for oral delivery of

S-nitrosogluta-thione
W. Wu
12:25
Amphiphilic Nucleic Acid Conjugates for Local Treatment of

Intestinal Diseases
E. Moroz
15:00
Invited talks: Oral Drug Delivery
Short talks: Nanoparticles & Vesicles
Recent Challenges in Oral Controlled-Release Drug Delivery

M. Lueck
The effect of using different nebulisers on the delivery of

Amphotericin B and Cisplatin Non-Ionic Surfactant Vesicles
M. Puig

Oral Delivery
Pulmonary Delivery
15:20
Ex vivo and in vivo siRNA delivery to activated T cells as novel

anti-inflammatory asthma therapy
Y. Xie
Dermal preparations
Physical Pharmacy
Preformulation
15:40
Gene Delivery
Therapeutic Index Issues around Oral Peptide Permeation

Enhancers
D. Brayden
Chitosan-iron-based nanogels for the cellular delivery of polyphosphate drugs

G. Giacalone
09:00 20:00; all day
16:00
Anti-E6/E7/MCL1 pegylated lipoplexes for a vaginal treatment

of cervical cancer
A. Lechanteur
16:20
Orodispersible Dosage Forms

D. Djuric
Delivery of Andrographolide to the brain by human serum

albumin nanoparticles
M. Bergonzi
16:40
Percutaneous absorption of benzophenone-3 loaded lipid

nanoparticles and polymeric nanocapsules: a comparative
study
E. Gilbert

Amphithtre Royal
La Nef
Amphithtre Clovis
09:00
Invited talks: Smart Drug Delivery Systems
Short talks: Advanced Drug Delivery
Progresses in Anticancer Drug Delivery by Polymer Conjugation

G. Pasut
Modifications of the stratum corneum barrier structure and

function introduced by freezing: consequences for drug
permeation studies
L. Roussel

09:20
In vitro phage display as a strategy to enhance the skin

penetration of heparins
S. Franz
Parenteral Delivery
Quality Assurance
09:40
3D Printing
C. Roberts
Quality Control & PAT

Stability Testing
Hyaluronic acid gels containing liposomes for the sustained

delivery of a corticoid to the inner ear
N. El Kechai
Technical Innovations
Green & Sustainable Pharma
10:00
Mesoporous phospholipid particle as a novel drug delivery

platform
K. Kawakami
In-vitro/In-vivo Correlations
09:00 17:00; all day
10:20
Smart Drug Delivery from an industrial perspective

P. Gellert
Thalidomide nasal powders for local treatment of nose

bleeding in hereditary hemorrhagic telangectasia
V. Chiapponi
10:40
In vitro estimation of drug delivery to stenosed coronary

blood vessels via drug-coated balloon catheters
A. Seidlitz
11:30
Amphithtre Royal
Plenary lecture: Advances in Pulmonary Drug Delivery, Hartmut Derendorf
15:00
Invited talks: Peptide and Protein Delivery
Short talks: Development & Manufacturing of

Solid Dosage Forms
Protein and Peptide Delivery: Current State of the Art

W. Hennink
Thermodynamics of API/Polymer Amorphous Formulations

G. Sadowski

15:20
Hot-melt extrusion of polyvinyl alcohol and plasticizer for

oral immediate release applications
W. De Jaeghere
Parenteral Delivery
Quality Assurance
15:40
Quality Control & PAT
Challenges and advances in vaccine delivery

D. O Hagan
Stability Testing
Melt blowing and electrospinning for dissolution enhancement

A. Balogh
16:00
Exploring the Use of Pressurised Gyration for Large Scale

Manufacture of Pharmaceutical Nanofibres
B. Raimi-Abraham
09:00 17:00; all day
16:20
Novel Application Systems for Transdermal Vaccine Delivery

H. Spilgies
PAT tools for the control of the manufacturing processes of

co-extruded implants, tablets and capsules
F. Krier
16:40
The Application of Novel nano-Thermal and Imaging

Techniques for Monitoring the Drug Distribution within
PLGA Microspheres
M. Zhao
Te
T
e chnolo
c h n o l o gic
gica
all L ac ttose
o se E xcipient
x c i p i en t s
Quality Assurance/Quality Control & PAT

169 In vitro dissolution behavior of extended release theophylline tablets in ethanolic media
K. Knop and P. Kleinebudde
170 BIORELEVANT DISSOLUTION METHOD IN QUALITY CONTROL OF DRUGS CONTAINING
API IN THE FORM OF SALTS OF WEAK ACIDS
J. Muselk, A. Franc, R. Gonc, D. Vetch, D. Majerckov and V. Durovcov
171 Improvement of pharmacists service in Pharmacy Belgrade
J. Bjeletic
Stability Testing
172 Evaluation of stability of bupivacaine hydrochloride 0.5% solution for injection under
non-temperature controlled conditions
A. Zygler, B. Kubiak, R. Lunio, A. Kot-Wasik, W. Sawicki and K. Wlodarski
173 Interaction and stability of biomolecules
A. Audfray and M. Terray
174 Investigation into a Potential Stabilizer for Moisture Induced Amorphous-Amorphous
Phase Separation of Solid Dispersions
C. Orive and M. Zhao
175 Analysis of Nano-sized Particles for the Precise Engineering of Drug Delivery Systems
for Nanomedicine Applications
C. Roesch, M. Broom and R. Vogel
176 Explicit Identification of Sub-Visible Particulates in Solution-Phase BioFormulations:
A Hybrid Approach
M. Terray and K. Dahl
177 Is Ion Mobility Mass Spectrometry the Missing Tool in Polymer Drug Delivery
Development?
J. R. N. Haler, D. Morsa, J. Far, P. Lecomte, C. Jrme and E. De Pauw
178 New perspectives for fabrication and analysis of biomimetic electrospun scaffolds for
skin tissue engineering applications
V. Planz, S. Seif and M. Windbergs
179 Stability and Structure of Therapeutic Proteins
S. Kenyon and M. Terray

39

180 Particle engineering of cocrystals using a solvent-free approach by spray congealing
. Duarte, M. Pereira, L. Padrela, J. F. Pinto and M. Temtem
181 Release profile and antioxidant activity evaluation of two topical gels enriched with
bioactive extracts from agro-industrial coffee wastes
M. Allegro, J. Marto, C. Montoya, N. Oliveira, S. Gonalves, A. Paiva, S. Barreiros, P. Simes,
L. Gonalves and H. Ribeiro
182 Selection of a Discriminant Dissolution Test for Extrudates Containing Itraconazole
J. Thiry, F. Krier, A. Pestieau and B. Evrard
40

Acknowledgements
We thank our sponsors:
Main sponsor
Platinum Sponsor
Silver sponsor
Bronze sponsor

41
10th World Meeting on Pharmaceutics, Biopharmaceutics
and Pharmaceutical Technology

4th 7th April 2016
SECC, Glasgow, Scotland
SEE YOU IN GLASGOW IN 2016

Find out more
42

SPONSORS
We thank our sponsors

43
Sirius Analytical Main sponsor

BOOTH 18
Sirius Analytical is the market leader in instrumentation and CRO services for measurement of pKa, logP/logD, Solubility and Dissolution
in aqueous, solvent, biorelevant media and in the presence of formulation additives.
Our unique solutions for automated supersaturation measurement
reveal new insights about the pH-dependent supersaturation a compound can exhibit and how supersaturation may be enhanced or
suppressed via the use of formulation additives and excipients.
With facilities in the US and UK Sirius offers global coverage with detailed and reliable analysis, expert
staff and rapid turnaround.
Contact
Paul Whittles
Forest Row Business Park
Station Road, Forest Row
East Sussex, RH18 5DW
United Kingdom
Phone: +44 1 34 28 20 72 0
Fax:
+44 1 34 28 20 72 5
E-mail: sales@sirius-analytical.com
www.sirius-analytical.com
Advantest Platinum sponsor

BOOTH 17
A world-class technology company, Advantest is the leading producer of
automatic test equipment (ATE) for the semiconductor industry and a
premier manufacturer of measuring instruments. The companys leadingedge systems and products are integrated into the most advanced semiconductor production lines in the world.
The company also focuses on R&D for emerging markets that benefit
from advancements in nanotech and terahertz technologies, and has recently introduced critical multi-vision metrology scanning electron microscopes and 3D imaging analysis tools for pharmaceutical and industrial applications. Founded in Tokyo
in 1954 has subsidiaries worldwide.
Contact
Anthony Petrolonis
Director TAS Sales +
Business Development
508 Carnegie Ctr. # 102
NJ 08540 Princeton
USA
44
Phone: +1 6 09-89 77 32 6
E-mail: anthony.petrolonis@advantest.com
www.advantest.com
armor pharma Platinum sponsor

BOOTH 13
ARMOR PHARMA manufactures and markets 3 ranges of pharmaceutical
grade lactose for all your applications:
- ARMOR PHARMA lactose monohydrate: sieved & milled lactose
- EXCIPRESS: lactose for Direct Compression
- EXCIPURE: lactose for Dry powder Inhalation
Its state of the art industrial facility, located in Brittany, FRANCE, is in full
compliance with pharmaceutical standards (cGMP, GDP, PAT) and enables
the production of lactose in line with pharmaceutical regulations: Ph-EU,
USP-NF and JP.
ARMOR PHARMAs ambition is to design solutions that best support customers development. Its positionning reflects this philosophy, centred on a question that makes sense: How would you like your lactose?
Contact
Phone: +33 2 99 18 39 29
E-mail: contact@armor-pharma.com
www.armor-pharma.com
Ashland Platinum sponsor

BOOTH 12
Since the 1950s, Ashland has provided solutions for tablet binding, film
coating and disintegration, controlled-release formulation and drug solubilization including Aqualon and Blanose sodium carboxymethylcellulose, Aqualon ethylcellulose, Aquarius coating systems,
AquaSolve and AquaSolve AS hypromellose acetate succinate (hydroxypropylmethylcellulose acetate succinate or HPMCAS), Benecel
methylcellulose and hypromellose, Cavamax*, Cavitron and Cavasol*
cyclodextrins, Klucel hydroxypropylcellulose, Natrosol hydroxyethylcellulose, Plasdone povidone and copovidone and Polyplasdone crospovidone.
*Registered trademark owned by Wacker Chemie AG. Ashland Inc. acts as a worldwide distributor for
Wacker.
Contact
Dr. Christian Mhlenfeld
Pharmaceutical Scientist
Phone: +49 2 11 74 9 11 38
E-mail: cmuehlenfeld@ashland.com
www.ashland.com
45
BASF SE Platinum sponsor

BOOTH 16
BASFs Pharma Ingredients & Services produces and markets a broad
range of active ingredients and excipients, as well as exclusive synthesis
services for the pharmaceutical industry. Our products are made using
the latest technologies, to the highest quality standards and in compliance with cGMP guidelines. The division has been a trusted partner to
the pharmaceutical industry for decades and customers benefit from our
unique expertise and extensive experience. Innovation is at the heart of
BASFs business and our excipients portfolio reflects our commitment to
research and development as highlighted by products such as Kollicoat
Smartseal 30D, Soluplus and Ludiflash or our end-to-end dermatology
portfolio.
Contact
Florian Wildschek
Chemiestr. 22
68623 Lampertheim
Germany
Phone: +49 6 21 60 76 93 4
Fax:
+49 6 21 60 76 93 2
E-mail: florian.wildschek@basf.com
www.pharma-ingredients.basf.com
DOW Pharma & Food Solutions Platinum sponsor

BOOTH 01
Dow Pharma & Food Solutions is a leader in global research, manufacturing and innovation of pharmaceutical excipients. It is dedicated to developing new technologies that will enhance the formulation, solubilisation
and delivery of active ingredients and boasts an outstanding portfolio of
cost-effective, high quality cellulose ethers and polyethylene oxide chemistries such as ETHOCEL, POLYOX, METHOCEL, WALOCEL and
AFFINISOL.
Dow has developed the AFFINISOL line of excipients to facilitate solubility enhancement:
Our AFFINISOL polymers are uniquely tailored to address the solubilization performance requirements
of your APIs, whether you have chosen to formulate via Spray-Dried Dispersion or Hot Melt Extrusion.
Contact
Marielle Fiore
Bachtobelstrasse 3
8810 Horgen
Switzerland
46
Phone: +41 4 47 28 25 73
Fax:
+41 4 47 28 31 50
E-mail: Fiore@dow.com
www.dowpharmaandfood.com
MEDELPHARM Platinum sponsor

BOOTH 17
MEDELPHARM, headquartered in Lyon, are specialist developers & manufacturers of innovative solutions for R&D Tablet Presses and powder characterization services.
In addition to manufacturing tablet presses MEDELPHARM also offers a
comprehensive range of Powder Compaction and Characterisation Services
- Powder analysis and characterization
- Theoretical and hand-on training on tablet presses and tools
- Troubleshooting in production
- Process optimization
MEDELPHARM R&D Tablet Presses portfolio includes:
- STYLOne CLASSIC Multilayer development press,
- STYLOne Evolution, the latest servo-mechanical Compaction simulator,
MEDELPHARM are exclusive distributors in France of ADVANTEST, FITZPATRICK, OHARA, QUADRO,
RIVA, Romaco Kilian and XPLore
Contact
Ingrid Coyle
E-mail: icoyle@medelpharm.com
Director Sales International &
12, rue des Petites Combes
01700 Beynost (Lyon)
France
www.medelpharm.com
Croda Europe Ltd Silver sponsor

We contribute to a healthier world by offering ingredients of superior
quality and providing unique formulation expertise, which help our pharmaceutical customers get the best possible performance from their active
ingredients.
Crodas portfolio is unsurpassed in excellence and designed to meet the
most stringent customer demands. Our proprietary manufacturing and
purification technology yields high quality products that meet the exacting
requirements of international Pharmacopoeia.
Crodas ongoing investment in GMP API technologies and R&D ensures the continual delivery of exceptional ingredients and the development of new speciality products to answer current and future health
and wellness needs.
Contact
Steve Mellor
E-mail: steve.mellor@croda.com
www.croda.com

47
LTS Lohmann Silver sponsor

LTS is the market leader in the development and manufacture of transdermal therapeutic systems (TTS) and oral thin films (OTF). As a B2B partner
to the pharmaceutical industry, LTS offers solutions at all stages of product
development, including feasibility assessments, research and development
of new formulations, production of clinical, as well as commercial scale
supplies, primary and secondary packaging. Products developed by LTS
comprise a multitude of innovations, like the first TTS for treatment of
Alzheimer and against Parkinson's Disease. Furthermore the innovation
potential of LTS resulted in OTF products for smoking cessation and for
the treatment of breakthrough pain.
Contact
Klaudia Haczkiewicz
Lohmannstr. 2
56626 Andernach
Germany
Phone: + 49 2 63 29 92 21 6
Fax:
+ 49 2 63 29 92 51 5
E-mail: klaudia.haczkiewicz@ltslohmann.de
www.ltslohmann.de
Sanofi Silver sponsor

Contact
www.sanofi.com
Seppic Bronze Sponsor

Excipients are our business, Health is our commitment: Our top priority is patient health and wellbeing. To that end, SEPPICs pharmaceutical division develops and supplies cutting-edge, effective excipients, including coating
solutions, injectables, adjuvants, functional excipients and dermopharmacy
polymers. Our specialty products are backed by exhaustive research, dedicated application laboratories and outstanding regulatory support. Combining
the strength and resources of a large group with the energy and responsiveness of a small company, SEPPIC is equally dedicated to both customer care
and product quality.
Contact
Kathleen Allain
22 Terrasse Bellini
92800 Puteaux
France
48
Phone: + 33 1 42 91 40 00
E-mail: kathleen.allain@airliquide.com
www.seppic.com
EXHIBITION

49
Index
ADRITELF
51
ADVANTEST
BOOTH 17
51
AGILENT TECHNOLOGIES
BOOTH 37
52
APGI
52
APV
53
AR2I - ANALYTICAL LABORATORY FOR DEVELOPMENT BOOTH 25
53
ARMOR PHARMA
BOOTH 13
54
ASHLAND
BOOTH 12
54
BASF SE
BOOTH 16
55
BAYER
BOOTH 44
55
CAPSUGEL
BOOTH 14
56
DOW PHARMA & FOOD SOLUTIONS
BOOTH 01
56
ELSEVIER
BOOTH 39
57
EQUIPEMENTS SCIENTIFIQUES (ES) / MICROFLUIDICS
BOOTH 10
57
EVONIK INDUSTRIES AG
BOOTH 02
58
GAMLEN TABLETING LTD.
BOOTH 20
58
GLATT
BOOTH 15
59
MALVERN INSTRUMENTS
BOOTH 08
59
MEDELPHARM
BOOTH 17
60
NISSO CHEMICAL EUROPE GMBH
BOOTH 26
60
SHIN-ETSU
BOOTH 19
61
SIGMA-ALDRICH
BOOTH 38
61
SIRIUS ANALYTICAL
BOOTH 18
62
SOTAX AG
BOOTH 09
62
STRATGIE SANT
BOOTH 21
63
SYMPATEC GMBH SYSTEM | PARTIKEL | TECHNIK
BOOTH 04
63
SYNERSY
BOOTH 11
64
THERMO FISHER SCIENTIFIC
BOOTH 07
64
FLOORPLAN
50
66

ADRITELF
Founded in 1972, A.D.R.I.T.E.L.F. (Italian Association for Pharmaceutical
Technology and Regulatory Affairs) is a non-profit making scientific society
with about 300 active members from all over Italy. This Italian Association
of Professors and Academic Researchers of Pharmaceutics, Pharmaceutical
Technology, Biopharmaceutics and Regulatory Affairs is devoted to the
promotion of interactions and collaborations, throughout the world,
among researchers from academy and industry within these scientific
fields. The society is also actively involved in the education and training of
young researchers in the field of pharmaceutics. Together with APGI (France) and APSTJ (Japan), the association is publishing the "Journal of Drug Delivery Sciences and Technologies". Main activities are the
biannual scientific congress and the cooperation with other scientific societies for the organization of international meetings.
Contact
Prof Anna Maria Fadda
Via Ospedale, 72
09100 Cagliari
Italy
Phone: +39 0 70 68 58 56 5
Fax:
+39 0 70 67 58 55 3
E-mail: mfadda@unica.it
www-3.unipv.it/adritelf/
Advantest Platinum sponsor

BOOTH 17
A world-class technology company, Advantest is the leading producer of
automatic test equipment (ATE) for the semiconductor industry and a
premier manufacturer of measuring instruments. The companys leadingedge systems and products are integrated into the most advanced semiconductor production lines in the world.
The company also focuses on R&D for emerging markets that benefit
from advancements in nanotech and terahertz technologies, and has recently introduced critical multi-vision metrology scanning electron microscopes and 3D imaging analysis tools for pharmaceutical and industrial applications. Founded in Tokyo
in 1954 has subsidiaries worldwide.
Contact
Anthony Petrolonis
Director TAS Sales +
508 Carnegie Ctr. # 102
NJ 08540 Princeton
USA
Phone: +1 6 09 89 77 32 6
E-mail: anthony.petrolonis@advantest.com
www.advantest.com

51
Agilent Technologies
BOOTH 37
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments,
services, consumables, applications and expertise, enabling customers to
gain the insights they seek.
Agilent has one of the broadest solutions portfolios of any company serving the pharmaceutical industry. Our solutions provide precise answers
for every segment of the pharmaceutical industry, from disease research
and drug discovery to drug development, manufacturing and quality
control. The start-to-finish solution set means customers can get products to market faster. Customers
trust us to help them test the purity of their therapeutics. Agilent also ensures that their instruments and
processes conform to the highest compliance regulations.
Contact
Luc Arnaud
3 Avenue du Canada
91978 Les Ulis
France
Phone: +33 6 72 99 03 25
E-mail: luc_arnaud@agilent.com
www.agilent.com/home
APGI
The APGI (Association de Pharmacie Galnique Industrielle/International
Society of Drug Delivery Sciences and Technology) was created in 1964 in
Paris, and is an association accessible to all, academics and individuals in
industry, who are concerned with pharmaceutical technology and the design, formulation and pharmacotechnical, biopharmaceutical and pharmacokinetic assessment of dosage forms and delivery systems, whether
pharmaceutical or dermopharmaceutical. The APGI has members covering
more than thirty different nationalities and counts contacts and friends in
over fifty countries. The APGI is a member of the FIP (Fdration Internationale Pharmaceutique).
The APGI is publishing the newsletter La Gazette and the scientific publication the Journal of Drug Delivery Sciences and Technology, which is the official journal of the APGI, the A.D.R.I.T.E.L.F. (Italy) and the
APSTJ (Japan).
Contact
Catharina Kroling
5 Rue Jean-Baptiste Clement
92296 Chateney-Malabry
France
52
Phone: +33 6 29 36 67 39
E-mail: apgi.asso@u-psud.fr
www.apgi.org

APV
The APV (International Association for Pharmaceutical Technology) is a
non-profit scientific association located in Mainz, Germany, which publishes its own scientific journal (EJPB European Journal of Pharmaceutics
and Biopharmaceutics). At present, the association is governed by an executive board consisting of 8 members.
Membership is granted upon application.
The APV organises approximately 100 events of various types ranging from expert meetings, seminars
and conferences to international scientific
congresses and exhibitions.
Contact
Dr Martin Bornhft
Kurfrstenstr. 59
55118 Mainz
Germany
Phone: +49 6 13 19 76 90
Fax:
+49 6 13 19 76 96 9
E-mail: apv@apv-mainz.de
www.apv-mainz.de
AR2i - Analytical Laboratory for Development

BOOTH 25
AR2i is a Contract Research Organisation (CRO) with expertise in chemical analysis methods and which carries out research and development
work in the fields of pharmaceuticals, parapharmaceuticals and cosmetics.
The AR2i laboratory was established in 1994 by scientists working in the
industrial, hospital and university sectors.
The main activity of AR2i lies in assisting its clients in the development of
new drugs with the view to obtaining a CTD agreement. The R&D support is a main dimension to AR2is
activity, its consists in development and validation of analysis methods, stability studies for pharmaceutical products, expert assessments for clients, in particular pharmaceutical laboratories and consultancy
firms. We develop analytical methods for raw materials, finished products or bulk substances.
Contact
Christian Sarbach
18-20 avenue Edouard Herriot
92350 Plessis-Robinson
France
Phone: +33 1 45 37 10 93
Fax:
+33 1 45 37 04 21
E-mail: contact@ar2i.fr
www.ar2i.fr

53
armor pharma Platinum sponsor

BOOTH 13
ARMOR PHARMA manufactures and markets 3 ranges of pharmaceutical
grade lactose for all your applications:
- ARMOR PHARMA lactose monohydrate: sieved & milled lactose
- EXCIPRESS: lactose for Direct Compression
- EXCIPURE: lactose for Dry powder Inhalation
Its state of the art industrial facility, located in Brittany, FRANCE, is in full
compliance with pharmaceutical standards (cGMP, GDP, PAT) and enables
the production of lactose in line with pharmaceutical regulations: Ph-EU, USP-NF and JP.
ARMOR PHARMA's ambition is to design solutions that best support customers development. Its positionning reflects this philosophy, centred on a question that makes sense: How would you like your lactose?
Contact
Phone: +33 2 99 18 39 29
E-mail: contact@armor-pharma.com
www.armor-pharma.com
Ashland Platinum sponsor

BOOTH 12
Since the 1950s, Ashland has provided solutions for tablet binding, film
coating and disintegration, controlled-release formulation and drug solubilization including Aqualon and Blanose sodium carboxymethylcellulose, Aqualon ethylcellulose, Aquarius coating systems,
AquaSolve and AquaSolve AS hypromellose acetate succinate (hydroxypropylmethylcellulose acetate succinate or HPMCAS), Benecel
methylcellulose and hypromellose, Cavamax*, Cavitron and Cavasol*
cyclodextrins, Klucel hydroxypropylcellulose, Natrosol hydroxyethylcellulose, Plasdone povidone and copovidone and Polyplasdone crospovidone.
*Registered trademark owned by Wacker Chemie AG. Ashland Inc. acts as a worldwide distributor for
Wacker.
Contact
Dr. Christian Mhlenfeld
Pharmaceutical Scientist
Phone: +49 2 11 74 9 11 38
E-mail: cmuehlenfeld@ashland.com
www.ashland.com
54

BASF SE Platinum sponsor

BOOTH 16
BASFs Pharma Ingredients & Services produces and markets a broad
range of active ingredients and excipients, as well as exclusive synthesis
services for the pharmaceutical industry. Our products are made using
the latest technologies, to the highest quality standards and in compliance with cGMP guidelines. The division has been a trusted partner to
the pharmaceutical industry for decades and customers benefit from our
unique expertise and extensive experience. Innovation is at the heart of
BASFs business and our excipients portfolio reflects our commitment to
research and development as highlighted by products such as Kollicoat
Smartseal 30D, Soluplus and Ludiflash or our end-to-end dermatology
portfolio.
Contact
Florian Wildschek
Chemiestr. 22
68623 Lampertheim
Germany
Phone: +49 6 21 60 76 93 4
Fax:
+49 6 21 60 76 93 2
E-mail: florian.wildschek@basf.com
www.pharma-ingredients.basf.com
Bayer
BOOTH 44
Bayer is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayers products and services are designed to benefit people and improve the quality of life.
At Bayer you have the opportunity to be part of a culture where we
value the passion of our employees to innovate and give them the
power to change.
We are looking forward to informing you about entry and career opportunities at Bayer.
Contact
Bayer University & Talent Relations
Hauptstrae 105
51368 Leverkusen
Germany
Phone: +49 2 14 30 64 00 0
E-mail: universitymarketing@bayer.com
www.career.bayer.de

55
Capsugel
BOOTH 14
Capsugel is a global leader in delivering high-quality, innovative dosage
forms and solutions to its customers in the health care industry. The
company's Hard Capsule business unit offers customers the broadest
portfolio of gelatin, vegetarian and other specialized capsule technologies. Capsugels Dosage Form Solutions (DFS) business unit solves customers most pressing product development challenges, including
bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. Capsugel DFS accelerates and improves product development through an array of proprietary
technologies including lipids and liquids, spray-dried dispersions, hot-melt extrusions, an through specialized manufacturing including FDA/MHRA-accredited finished dosage sites that can handle highly potent,
controlled substance, hormonal and oncology compounds. Headquartered in Morristown, N.J., Capsugel
serves more than 4,000 customers in more than 100 countries.
Contact
Phoenix Barringer
64550 Research Rd.
Morristown, N.J.,
USA
Phone: +1 5 41 38 24 10 0
E-mail: phoenix.barringer@capsugel.com
www.capsugel.com
DOW Pharma & Food Solutions Platinum sponsor

BOOTH 01
Dow Pharma & Food Solutions is a leader in global research, manufacturing and innovation of pharmaceutical excipients. It is dedicated to developing new technologies that will enhance the formulation, solubilisation
and delivery of active ingredients and boasts an outstanding portfolio of
cost-effective, high quality cellulose ethers and polyethylene oxide chemistries such as ETHOCEL, POLYOX, METHOCEL, WALOCEL and
AFFINISOL.
Dow has developed the AFFINISOL line of excipients to facilitate
solubility enhancement:
Our AFFINISOL polymers are uniquely tailored to address the solubilization performance requirements
of your APIs, whether you have chosen to formulate via Spray-Dried Dispersion or Hot Melt Extrusion.
Contact
Marielle Fiore
Bachtobelstrasse 3
8810 Horgen
Switzerland
56
Phone: +41 4 47 28 25 73
Fax:
+41 4 47 28 31 50
E-mail: Fiore@dow.com
www.dowpharmaandfood.com
Elsevier
BOOTH 33
Elsevier is a world-leading provider of information solutions that enhance
the performance of science, health and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of
knowledge and human progress. In pharmaceutical sciences, Elsevier publishes leading journals like Advanced Drug Delivery Reviews, the Journal
of Controlled Release, the European Journal of Pharmaceutical Sciences,
the European Journal of Pharmaceutics & Biopharmaceutics (with APV),
the International Journal of Pharmaceutics, and the Journal of Drug Delivery Science and Technology (with APGI, Adritelf and APSTJ).
Contact
Anne Marie Pordon
Radarweg 29
1043 NX Amsterdam
The Netherlands
Phone: +31 6 12 98 41 28
Fax:
+31 2 04 85 32 28
E-mail: a.pordon@elsevier.com
www.elsevier.com
Equipements Scientifiques (ES) / Microfluidics

BOOTH 10
We are an Exclusive producer of Microfluidizer high shear fluid processors. Microfluidizer Processor Technology is used for Emulsification (dispersion of one liquid phase into another liquid phase) and for dispersion
of a solid into a liquid.
The Microfluidizer processor excels at: Particle size reduction, Cell disruption, nano Emulsions, encapsulation and Liposomes.
The innovative technology solutions offered by Microfluidics are used
globally by laboratories for synthesis and formulation, as well as for production. The combined performance and scalability of Microfluidics
equipment is well known and acknowledged in the world of Nanotechnologies. 40 years serving customers worldwide with over 3000 machines for 2000 customers. Equipements Scientifiques (ES) is our local Partner in France for all inquiries relating to Microfluidcs products.
Contact
Daniel Guez
Equipements Scientifiques
127 rue de Buzenval
92380 Garches
France
Phone: +33 1 47 95 99 90
Fax:
+33 1 47 0 16 22
E-mail: bio@es-france.com
www.es-france.com
www.microfluidicscorp.com

57
Evonik Industries AG
BOOTH 02
Evonik, a global leader in specialty chemicals, with its Health Care Business Line provides pharmaceutical excipients, drug delivery technologies,
development services, and GMP manufacturing for oral and parenteral
formulations as well as active pharmaceutical ingredients.
Contact
Dr. Christian Thlig
Business Director Northern
and Western Europe
Phone: +49 6 15 11 8 35 12
Fax:
+49 6 15 11 8 84 35 12
E-mail: christian.thuelig@evonik.com
Kirschenallee
64293 Darmstadt
Germany
www.eudragit.com
www.resomer.com
Gamlen Tableting Ltd.

BOOTH 20
Gamlen Tableting Ltd developed and market the Gamlen Tablet Press
(GTP), a unique benchtop, computer controlled tablet press used for formulation development, product evaluation and small scale manufacturing. The GTP is ideal for use in both the laboratory and university
setting. It has been shown to accurately predict the compression behaviour of materials on high speed production machines operating at full
speed, and is an important tool for measuring the compactibility of drug
substances, excipients, and drug products. Its super-accurate force and
displacement measurement are also used to measure in-die compression
parameters such as Heckel and Kawakita plots.
Contact
Michael Gamlen
Phone: +44 1 15 91 24 27 1
Fax:
+44 1 15 91 24 27 8
Biocity Nottingham Pennyfoot Street E-mail: michael.gamlen@gamlentableting.com
Nottingham NG1 1GF
United Kingdom
www.gamlentableting.com
58

Glatt
BOOTH 15
Glatt Pharmaceutical Services develops and produces solid pharmaceutical dosage forms. Our focus is on multiparticulate systems such as pellets, micropellets and granules. Whether you are looking for optimal
bioavailablity or taste masking, improved solubility or stabilization of the
dosage form, we have the right solution for every challenge. Glatt Pharmaceutical Services brings together fundamentals, experience and innovative technology expertise. With our comprehensive services, we
support you from product idea to market launch.
For clinical studies and market supply, we manufacture medicines in bulk and efficiently bring your products to market. Our technical capabilities facilitate a seamless scale-up from the lab to commercial production scale, for which we conduct all requisite analytical studies and stability tests. These services are
provided in sites Binzen/Germany and in Ramsey, New Jersey in the United States.
Contact
Philippe Tschopp
Werner-Glatt-Str. 1
79589 Binzen
Germany
Phone: +49 7 62 16 64 50 6
E-mail: philippe.tschopp@glatt.com
www.glatt.com
Malvern Instruments
BOOTH 08
Malvern Instruments characterizes particles ranging from powders to
proteins. The new laser particle size analyzers measure size, charge,
shape and molecular weight. In 2014 Malvern acquired MicroCal and
sells and installs ITC (Isothermal Titration Calorimetry) and DSC (Differential Scanning Calorimetry). Malvern launched in January 2015 a new system called PEAQ for GPC/SEC which follows a new SEC MALS detector
in 2014. The company is also heavily involved in the Biosciences with 5
new instruments: Viscosizer using the Taylor dispersion, Morphologi G3
ID combining image analysis and Raman spectroscopy, Archimedes characterizing protein aggregates, Helix identifying chemical bonds with DLS
combined with Raman and Nanosight to count nanoparticles in complex
environments.
Contact
Michel Terray
30 rue Jean Rostand
91893 Orsay-Cedex
France
Phone: +33 1 69 35 11 65
Fax:
+33 1 60 19 13 26
E-mail: Michel.Terray@malvern.com
www.malvern.com

59
MEDELPHARM Platinum sponsor

BOOTH 17
MEDELPHARM, headquartered in Lyon, are specialist developers & manufacturers of innovative solutions for R&D Tablet Presses and powder characterization services. In addition to manufacturing tablet presses
MEDELPHARM also offer a comprehensive range of Powder Compaction
and Characterisation Services
- Powder analysis and characterization
- Theoretical and hand-on training on tablet presses and tools
- Troubleshooting in production
- Process optimization
MEDELPHARM R&D Tablet Presses portfolio includes:
- STYL'One CLASSIC Multilayer development press,
- STYL'One Evolution, the latest servo-mechanical Compaction simulator,
MEDELPHARM are exclusive distributors in France of ADVANTEST, FITZPATRICK, OHARA, QUADRO,
RIVA, Romaco Kilian and XPLore
Contact
Ingrid Coyle
Director Sales International &
12, rue des Petites Combes
01700 Beynost (Lyon)
France
E-mail: icoyle@medelpharm.com
www.medelpharm.com
NISSO CHEMICAL EUROPE GmbH

BOOTH 26
NISSO CHEMICAL EUROPE GmbH (NCE) was founded in 1989 as a subsidiary of Nippon Soda Co., Ltd. Tokyo, Japan. Based in Dsseldorf, NCE is
able to respond swiftly and effectively to customer needs both in Europe
and Africa. NISSO HPC (Hydroxypropyl Cellulose) is one of the key products for NISSO group. NCE distributes NISSO HPC to European, and
African market, offering a wide range of viscosities and particle size formats for wet granulation, direct compression, ODT, modified release,
and film coating applications. NISSO HPC is EP, USP/NF, and JP compliant.
Latest unique offering are special low viscosity grades of NISSO HPC.
Contact
Dr. Berna Ehlig
Berliner Allee 42
40212 Dsseldorf
Germany
60
Phone: +49 2 11 13 06 68 60
Fax:
+49 2 11 32 82 31
E-mail: ehlig@nisso-chem.de
www.nissoexcipients.com
Shin-Etsu
BOOTH 19
Shin-Etsu began producing pharmaceutical excipients in 1962. Since
then, thanks to feedback from our customers and inspection by the FDA,
we have further developed and improved our quality and control systems
to high standards. Shin-Etsu's cellulose excipients can make a valuable
contribution in various areas of pharmaceutical technology, for example
as film coatings (Pharmacoat), solid dispersion (Shin-Etsu Aqoat
HPMCAS), matrix tablets (Metolose SR), enteric coating (HPMCP and
HPMCAS)and ODT (L-HPC & SmartEx).
Our technical services we have now opened a new application laboratory for customer trials, and are
now offering QbD samples kits for your development. Please visit the booth for more information.
Contact
Veronique Henner
E-mail: Veronique.Henner@SE-PFMD.com
www.se-pfmd.com
SIGMA-ALDRICH
BOOTH 38
Sigma-Aldrich is a leading Life Science and High Technology company.
Our biochemical and organic chemical products and kits are used in
scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical
and other high technology manufacturing.
Contact
Dr Bruno Lelong
LIsle DAbeau Chesnes
BP 701
38297
Saint Quentin Fallavier
France
Phone: +33 6 03 36 33 27
E-mail: bruno.lelong@sial.com
www.sigmaaldrich.com/materials-science.html

61
Sirius Analytical Main sponsor

BOOTH 18
Sirius Analytical is the market leader in instrumentation and CRO services for measurement of pKa, logP/logD, Solubility and Dissolution
in aqueous, solvent, biorelevant media and in the presence of formulation additives.
Our unique solutions for automated supersaturation measurement
reveal new insights about the pH-dependent supersaturation a compound can exhibit and how supersaturation may be enhanced or
suppressed via the use of formulation additives and excipients.
With facilities in the US and UK Sirius offers global coverage with detailed and reliable analysis, expert
staff and rapid turnaround.
Contact
Paul Whittles
Forest Row Business Park
Station Road, Forest Row
East Sussex, RH18 5DW
United Kingdom
Phone: +44 1 34 28 20 72 0
Fax:
+44 1 34 28 20 72 5
E-mail: sales@sirius-analytical.com
Sotax AG
BOOTH 09
SOTAX, founded in 1973 in Switzerland, is a fast-growing group leader
in providing high-quality dissolution testing systems, composite assay
and content uniformity workstations, and physical tablet testing instruments for the pharmaceutical industry throughout the world. SOTAX
also offers SPS Pharma Services (CRO), a contract research lab dedicated
to dissolution testing research, and integrated the Zymark automation
product line, resources and services in 2008. Since 2013, the Dr. Schleuniger Pharmatron brand completes the SOTAX product portfolio and
expertise in the physical testing segment.
Contact
Samir Haddouchi
SPS Pharma Services
3 rue Chateaubriand
45071 Orleans Cedex 2
France
62
Phone: +33 6 18 74 34 53
Fax:
+33 2 34 59 72 60
E-mail: samir.haddouchi@sps-pharma.com
www.sps-pharma.com

Stratgie Sant
BOOTH 21
Stratgie Sant is an independent French company providing assistance and advisory services to Pharmaceutical Companies.
Thanks to our proven expertise in Pharmaceutical Development, Project Management and Regulatory Affairs, we support our clients
throughout all phases of the product development. We helps clients
to achieve the best development strategy, take in charge each stage
of the project, select and coordinate all sub-contractors from the raw
material sourcing to the registration batches manufacturing, including completion of the technical parts of the dossier. Our regulatory
expertise enables us to advise clients in elaborating the most efficient
registration strategy. We assure the writing (CTD and eCTD) and the registration of the dossier, including
its follow-up all over the product life cycle.
Contact
Didier Terracol
19, rue Georges Clemenceau
78000 Versailles
France
Phone: +33 1 42 86 86 00
Mobile:+33 6 06 71 39 44
E-mail: didier.terracol@strategiesante.com
www.strategiesante.com
Sympatec GmbH System | Partikel | Technik

BOOTH 04
Sympatec develops, manufactures, sells, services and supports an innovative range of best instruments for particle size and shape analysis in laboratory and process for customers worldwide. With
continuous innovations in the technological fields of laser diffraction,
dynamic image analysis, ultrasonic extinction and photon cross-correlation spectroscopy (PCCS), Sympatec makes a prominent contribution to the development, production and quality control of most
challenging particulate systems. Typical applications cover dry
powders and granules, fibres, suspensions, emulsions, gels, sprays
and inhalants within a size range from 1 nm to 34,000 m. Modular
instruments show great versatility and can be adapted to the specific task within your laboratory. The
proven measurement technologies are also available for integration into your process. Moreover, all instruments reliably deliver most accurate, reproducible and comparable results at shortest measuring
times. Sympatec The Particle People.
Contact
Philippe Violle
18 rue Charles de Gaulle
91400 Orsay
France
Phone: +33 1 69 18 19 55
Fax:
+33 1 69 28 16 73
E-mail: pviolle@sympatec.com
www.sympatec.com

63
Synersy
BOOTH 11
Synersy is an independent French company specialized in sales & services for dissolution, transdermal diffusion and physical testing.
Synersy is working with several reliable suppliers all over the world,
manufacturing high quality systems & accessories:
- Hanson: world leader in dissolution test technology for the
pharmaceutical industry
- Cambtek RES: new technology system for improvement of content
uniformity analysis
- Argus Dissolution from Solvias: most powerful, flexible & multipurpose dissolution software
- Electrolab physical testing systems & USP4: high quality & cost effective systems
- Uniflex: innovative system for dissolution vessels cleaning.
Contact
Celine Terrats
13 Rue Lavoisier
66600 Rivesaltes
France
Phone: +33 9 63 69 53 97
Fax:
+33 4 68 51 45 31
E-mail: c.terrats@synersy.fr
www.synersy.fr
Thermo Fisher Scientific

BOOTH 07
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000
employees in 50 countries. Our mission is to enable our customers to
make the world healthier, cleaner and safer. We help our customers
accelerate life sciences research, solve complex analytical challenges,
improve patient diagnostics and increase laboratory productivity.
Through our premier brands Thermo Scientific, Applied Biosystems,
Invitrogen, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.
Contact
Cristina Zara
Phone: +39 02 95 05 92 26
Fax:
+39 02 95 05 92 56
E-mail: cristina.zara@thermofisher.com
www.thermoscientific.com
64

INSPIRING
TECHNOLOGIES
Your partner
for transdermal patches
and oral thin films
LTS LOHMANN THERAPIE-SYSTEME AG

LOHMANNSTRASSE 2, 56626 ANDERNACH, GERMANY, WWW.LTSLOHMANN.DE

65
Floor Plan Reims, France 13 - 14 April 2015
BUREAUX
REIMS
EVENEMENTS
REIMS
EVENEMENTS
BUREAUX
MENTS
TERRASSE
WARDROBE
SECURITY
Poster pannels
Poster pannels
27
28
29
30
EVONIK
03
BUFFET
1,662
&+(0,&$/
26
Platinum
Sponsor
01
DOW
02
BUF
SOTAX
Poster pannels
31
35
Poster pannels
32
34
Poster pannels
33
36
ES/MICROFLUDICS
SYNERSY
11
10
09
GAMLEN
TABLETING
Main Sponsor
18
SHINETSU
20
S,5,86$1$/<7,&$/
Platinum
Sponsor
ASHLAND
12
P
S
Platinum
Sponsor
$
3+
$'9$17(67
0('(/3+$50
19
1
Pl
S
B
Poster pannels
AGILENT
$5L
STRATEGIE
SANTE
37
BUFFET
BUFFET
22
23
21
24
$QDO\WLFDO /DERUDWRU\
IRU 'HYHORSPHQW
25
6,*0$
$/'5,&+

Poster pannels
ENT
to Exh
RECEPTION DESK
(Level 0)
Booths 9m2
Booths recommended to
PLATINIUM Sponsors >
High Tabl
Available
BOOKED
Poster pa
Electricity
Available
66

BUREAUX OFFICE DE TOURISME DE REIMS

TERRASSE
TERRASSE
WARDROBE
LEVEL 1
(/6(9,(5
39

FET
40
APGI Desk
SYMPATEC
Equipped 8 m2 booths with a meeting room

Meeting Meeting
Room
Room
45
BAYER Meeting Meeting

Room
Room
4
46
45
43
latinum
Sponsor
5025
+$50$
1
)FMQDesk
CAREER CENTRE
14
GLATT
0$/9(51
STORAGE AREA
(WILL BE CLOSED TO PARTICIPANTS)
ADRITELF
Desk
7+(502
6&,(17,),&
15
16
EXHIBITOR
&$368*(/
14
atinum
ponsor
BASF
APV Desk
BUFFET
41
42
Poster pannels
Paravents
LEVEL 1
Paravents
To Conference rooms
RANCE
hibition
es
Exihibition-Lunch/Coffee Break - Champagne reception Area
annels
Manifestation : ADRITELF - APGI -APV
y in the floor if needed

Dates : 13 & 14 April 2015
= 2 mtres
67
Power of Purity
Looking to enhance the bioavailability,
delivery and efficacy of your dosage form?
With Crodas high purity functional excipients and formulation expertise you
can discover how to get the best performance from your active ingredients.
Croda offers a complete range of products including high purity
multicompendial solvents, solubilisers and surfactants to meet your
needs across all delivery forms. Our Super RefinedTM excipients will
optimise the delivery and stability of your APIs and drug formulations
while maintaining API integrity.
To discover how to maximise oxidative stability, optimise API stability
and increase API delivery contact us:
www.crodahealthcare.com
Europe, Middle East & Africa hc-europe@croda.com
Innovation you can build on
TM
A new range of ingredients for nutri-cosmetics

to improve Skin
moisturization and enhance
Beauty
ENCAPSULATION
SOLUTIONS
At SEPPIC, we know that every application has unique challenges and

requirements.
We can offer excipients and solutions for various encapsulation
technologies, including:
Prilling
Hot Melt Coating
Coacervation
For more information, contact:
Mr Yves DUCCINI
Business Development Manager
Email: yves.duccini@airliquide.com
Phone: + 33 6 82 81 87 84
80%
9 high-potential projects
4.8 bn
of our development
projects are biologics
are in late-stage*
of investment in R&D
in 2013
EXPLORING THE BOUNDARIES OF MEDICAL INNOVATION

Sanofi has created an open innovation model, based on solid collaborations with its partners
and the scientific community. With this new R&D approach, Sanofi can meet its main challenges:
accelerating the transformation of scientific innovation into targeted therapeutic solutions for
patients and developing new biologic entities.
www.sanofi.com
DRUG
DELIVERY
EVERYTHING UNDER CONTROL FROM R&D TO

SCALE-UP AND PRODUCTION
MEDELPHARM S.A.S
12, rue des petites
Combes, Z.I. Nord
F-01700 Beynost,
France
+33 478 976 210
www.medelpharm.com
Medelpharm headquartered in Lyon, is a specialist developer and manufacturer

of unique solutions for R&D tablet presses & powder characterization services
Medelpharm is an exclusive distributor in France, Switzerland and Belgium of
ADVANTEST Fitzpatrick OHara Quadro Romaco Kilian and Xplore
Protect. Deliver.
Stabilize. Enhance.
From matrix to film coating, your full-service

pharmaceutical technology resource
Innovative solutions
Unparalleled product portfolio
Cellulosic and vinyl pyrrolidone platforms
Global cGMP manufacturing plants
QbD services
With good chemistry great things happen.
New Product
Sirius Scissor
Subcutaneous injection site simulator
a
Interested in
?
o
FREE dem
of
Speak to one
m
the Sirius tea
on our stand
today.
The only in vitro tool capable of determining the

behaviour and bioavailability of formulations
following injection into man.
Sirius Analytical
Forest Row Business Park, Forest Row, East Sussex, RH18 5DW, UK
Telephone:+44 (0) 1342 820720 Fax:+44 (0) 1342 820725
Email: sirius@sirius-analytical.com www.sirius-analytical.com

Abstractbook Reims2015

Diunggah oleh

Informasi Dokumen

Judul Asli

Hak Cipta

Format Tersedia

Bagikan dokumen Ini

Bagikan atau Tanam Dokumen

Opsi Berbagi

Apakah menurut Anda dokumen ini bermanfaat?

Apakah konten ini tidak pantas?

Hak Cipta:

Format Tersedia

Abstractbook Reims2015

Diunggah oleh

Hak Cipta:

Format Tersedia

ABSTRACTBOOK

Reims, France 13 - 14 April 2015

Chairs and Committees

Co-Chairs of the Conference

Programme Committee Chair

International Support Pannel

1st European Conference on Pharmaceutics Drug Delivery

Welcome reception at the Centre des Congrs Reims

Opening hours: business office and registration desk

BOULEVARD MAURICE NOIROT

1st European Conference on Pharmaceutics Drug Delivery

Monday, 13 April 2015

1st European Conference on Pharmaceutics Drug Delivery

Tuesday, 14 April 2015

09:20 IN VITRO PHAGE DISPLAY AS A STRATEGY TO ENHANCE

1st European Conference on Pharmaceutics Drug Delivery

Advanced Drug Delivery Systems

Lipid-based formulations as a way to improve the solubilization of cinnarizine

A new RNA delivery platform for tumor immunotherapy

Anti-inflammatory properties of synbiotic loaded chitosan-Ca-alginate

Cationic lipid-free cationic nanoemulsions - a novel approach for the treatment of

Charge reversal inulin-doxorubicin conjugate as tailor-made tool for cancer

Development and characterization of SEDDS containing babassu oil associated with

DEVELOPMENT AND CHARACTERIZATION OF SELF NANOEMULSIFYING SYSTEM (SNEDDs)

Development of internally self-assembled lipid-based systems for vaccine delivery

Development of microsponges as drug delivery carriers using multivariate analyses

1st European Conference on Pharmaceutics Drug Delivery

Development of mucoadhesive drug delivery systems by precipitation of chitosan

Does cinnarizine form amorphous complexes with lipids during digestion of

Drug delivery in UTI treatment new perspectives by mimicking uropathogenic

Drug-Loaded Silica for Oral Formulations

FUSED DEPOSITION MODELING (FDM) FOR 3D PRINTING OF DRUG DELIVERY CAPSULES

Generation and characterization of small single domain antibodies inhibiting human

Improving the delivery of vaginal dosage forms

In situ Gel Formulation for Intravesical Gemcitabine Hydrochloride Installation

Influence of size and protein concentration on the cross-linking degree of serum

Influence of the Ester Group Structure of Modified Alginates on the Preparation of

Interaction studies of Memantine loaded biodegradable polymeric nanoparticles

Lipid self-assembled structures as carriers for antimicrobial peptides

1st European Conference on Pharmaceutics Drug Delivery

Lyophilized microemulsions: the influence of heating on the droplet size and

Microcontainers improve oral bioavailability of furosemide

Mucoadhesion of thiolated poly(aspartic acid) polymers for ophthalmic use

Nanotubes-in-Microgel Oral System (NiMOS) by prilling for Protein Delivery

Phosphorous dendrimers siRNA complexes for treatment of chronic inflammation

PLATELET LYSATE EMBEDDED SCAFFOLD FOR WOUND HEALING: IN VITRO AND

PREPARATION OF MODIFIED RELEASE DRUG LOADED HPMC-AS MATRIX

Redox-responsive mesoporous silica as carriers for controlled drug delivery

Serum Albumin-Alginate Microparticles Prepared by Transacylation:

Serum Albumin-Alginate Microparticles Prepared by Transacylation: Physicochemical

SmartCrystals - stability in dermal hydrogels and creams

SOLVENT FREE APPROACH FOR ENHANCEMENT OF DRUG SOLUBILITY USING

Synthesis and Characterization of Poly(-Caprolactone)- vitamin E TPGS Copolymers

1st European Conference on Pharmaceutics Drug Delivery

Targeted Poly-(L)-glutamic acid drug delivery systems for intravesical therapy of

The drug-initiated method: a convenient approach for the synthesis of efficient

Controlled Drug Delivery

CHARACTERIZATION OF SUPRAMOLECULAR SYSTEMS CONTAINING FENBUFEN,

Controlled release from drug/Eudragits delivery systems

Controlled Release Implants prepared by compression of spray-dried PLGA/water-soluble

Controlled release of quercetin encapsulated in biopolymer films modulated by

Development of novel formulations for organoboron drugs by association

Importance of Diffusion and Limited Drug Solubility in Silicone Matrices for